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Phosphorylation regulates many cellular processes. However, its role in mRNA
deadenylation, a process to remove poly adenosines from the mature mRNA 3’ end tail,
is unclear. The length of poly(A) tail determines mRNA stability and translation
efficiency. Poly(A)-binding protein (PABP), which binds to newly synthesized poly(A)
tails homogeneously and is known as a scaffold protein for PAM2 motif-containing
proteins, plays a pivotal role in the shortening of poly (A) tails. This study is to examine
the role of phosphorylation of PAM2 motif–containing proteins in regulating their
interactions with PABP and mRNA deadenylation function.
The PAM2 motif, a region required for binding PABP C-terminal domain, is
embedded inside the intrinsically disordered region (IDR) of its containing proteins. IDR
is known to be a favored site for phosphorylation, and the PAM2 motif is surrounded by
numerous potential phosphorylation sites. To test whether phosphorylation plays a role
in controlling the interaction between PAM2-containing proteins and PABP, this study
used complementary approaches (to alter the phosphorylation level of PAM2 motifcontaining proteins biochemically and to create phospho-mimetic (PM) and nonphosphorylatable (NP) mutants). The results showed that reducing or increasing
phosphorylation of these proteins can enhance or diminish their interaction with PABP,
respectively. Furthermore, diminished PABP interaction compromises the biological
functions of these proteins in deadenylation and miRNA-mediated gene silencing.
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Using Tob2-PABP interaction as a model, this study provides more insight into the
mechanism by which phosphorylation of PAM2 motif–containing proteins regulates their
interactions with PABP. The data presented here suggest that the two PAM2 motifs of
Tob2 interact with PABP in a synergistic rather than addictive manner. Multiple
phosphorylation induced by JNK1 in Tob2 IDR compromises Tob2-PABP interaction. A
critical site for phosphorylation of Tob2 was identified. Global mRNA deadenylation can
be regulated by phosphorylation status of this site.
Collectively, this work provides a new concept, in which signaling pathways
crosstalk may tune global deadenylation rates through phosphorylation of PAM2 motifcontaining proteins to modify their PABP affinity.
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Introduction
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1.1 Messenger RNA biogenesis and poly(A) tail functions
mRNAs are ribonucleic acids transcribed from DNA by RNA polymerase II in
eukaryotic cells. They only account for ~3% of the population of total RNAs; however,
they encode for every protein in a cell (1,2). Immediately following the start of
transcription, a 7-methylguanosine nucleotide is added to the 5’ end of mRNA (3). This
precursor mRNA then goes through splicing (4) to remove non-coding intron sequences
while polymerase II continues transcribing. Before the end of transcription, pre-mRNA is
cleaved and released by Cleavage and polyadenylation specificity factors (CPSFs) (5).
Immediately after the cut, adenosine monophosphates are added to the 3’end by
polynucleotide adenylyltransferase at the site downstream of polyadenylation signal
sequence AAUAAA. This process is known as polyadenylation (6), which is considered
the last step of mRNA maturation in the nucleus.
The majority of mRNAs in a eukaryotic cell are modified by polyadenylation with
the notable exception of those coding for histone protein during maturation process. The
homogeneous poly(A) tail is known to stretch 250 and 100 adenines in length in
mammals and yeast, respectively. Once poly(A) tail starts to form, poly(A)-binding
proteins (PABPs) associate with the tail forming a tail complex. This tail-PABPs complex
plays critical roles throughout a majority of steps in the mRNA life cycle (Figure 1.1)
including, splicing (7), nucleus exportation (8), subcellular localization (9), translation
initiation, repression, and termination (10), microRNA-mediated gene silencing (11), and
mRNA turnover (1,2,10,12,13).
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Figure 1.1 mRNA life cycle. Messenger RNA (green line) is transcribed by polymerase II
(blue oval). Immediately following synthesis, 5’ of mRNA is methyl capped (green solid
circle). Splicing (blue loop) occurs while transcribing. At the end of transcription, mRNA
is cleaved by CPSF, followed by polyadenylation (red A). PABPs (orange oval) harbor
on the poly(A) tail once it is synthesized. The PABPs-poly(A) tail complex is involved in
mature mRNA nuclear export, cellular localization, translation, and deadenylation.

1.2 Deadenylation
Removal of a poly(A) tail from 3’ end is the major way to regulate mRNA
functions in a cell (14,15). This process, deadenylation, is carried out mainly by
deadenylase complex Ccr4-Caf1 in all eukaryotic cells. In mammals, a deadenylase
complex Pan2-Pan3 is found to be responsible for the shortening of poly(A) tail in the
early stage of deadenylation from 250nt to ~110nt. The half length poly(A) tail is then
chopped by Ccr4-Caf1 complex from ~110bp to 10bp. This two-phased (16) model was
based on the observation that poly(A) tail shortening is in a homogeneous slow
distributive enzymatic digestion fashion during the first phase. In this phase, the mRNA
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body has no detectable decay. Second phase deadenylation follows when the Ccr4-Caf1
complex hydrolyzes the tail in a processive enzymatic digestion fashion. The mRNA
body is decayed during this phase (17). In addition, deadenylation, in most cases, is
ahead of, and required for, mRNA body decay. Furthermore, the deadenylation rate may
be controlled by cis-acting elements. Followed the default state of deadenylation in
which all polyadenylated mRNAs undergo tail shortening, decapping is carried out by
Dcp1/2 before Xrn1 performs exonucleolytic digestion from 5’ to 3’ direction (18-20). This
is the major cytoplasmic mRNA decay pathway (Figure 1.2). In some cases, mRNA
decay can be independent to deadenylation, where exosome chops the mRNA from
3’à5’ fashion, regardless of decapping (21,22).

Figure 1.2 mRNA decay pathways. A mature mRNA has 5’ methyl cap and 3’ poly (A)
tail (red A) harbored with PABPs (orange oval). In majority circumstances (red thick
arrow), mRNA decay is deadenylation-dependent. It goes as follows: first (B)
deadenylation, where Pan2-Pan3 (not depicted) and Ccr4-Caf1 deadenylase complexes
digest poly (A) tail to oligomer level, then second (C) decapping, where Dcp1/2 removes
the methyl cap, and third (D) decay of mRNA body by Xrn1 takes place. In some cases,
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(red thin arrow), nuclease exosome will digest the mRNA body from 3’ end after the
deadenylation skipping decapping process. In other cases, mRNA decay is
deadenylation-independent (black thin arrow). It can either be directly digested by
exosome or can be decapped, followed by Xrn1 digestion.

1.3 Poly(A)-binding proteins
Poly(A)-binding protein (PABP) binds to poly(A) tail right after mRNA
polyadenylation has occurred. It has been shown that each PABP can interact with ~25
adenylate residues of poly(A) tail (23). Accordingly, there will be around 4 PABPs and 10
PABPs bound on newly synthesized poly(A) tail to control mRNA functions in yeast and
mammals, respectively. The PABP gene family is evolutionarily highly conserved and
known for its role as a scaffold protein, providing an access point for regulatory proteins
to control the length of poly(A) tail (24-26). In mammalian cells, five PABPs have been
identified (Figure 1.3). Among them, four (PABPC1, PABPC3, iPABP, and X-linked
PABPC5) are cytoplasmic forms and one (PABPN1) is a nuclear form. PABPC3 is testisspecific while iPABP is inducible protein (24). In cytosol, PABPC1 is the most abundant
form and contributes significantly to the function of poly(A) tail in cytoplasm including
translation initiation/termination, mRNA translocation, and mRNA stability. In the
nucleus, PABPN1 controls the length of polyadenylation (27) and contributes to mRNA
splicing (28) and nuclear exportation (29).
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Figure 1.3 Structure and motifs of human poly(A) binding protein family. All members of
PABP except nuclear PABPN1 have RRM motifs (blue box) close to N-terminal for
poly(A) RNA interaction. Three members have C-terminal MLLE domain for PAM2 motif
interaction. Within the cytoplasmic form of PABPs (PABPC1, PABPC3, PABPC4, and
PABPC5), PABPC1 expression is predominant and is playing the most critical role. One
nuclear PABPN1 is playing roles in pre-mRNA maturation and export.

Structurally, all PABPs in mammals contain RNA-binding motifs (RRM) at Nterminal for RNA binding, while only three PABPs (PABPC1, PABPC3, iPABP) have a
unique MLLE motif located in an additional region at the C-terminal end. MLLE
represents the conserved signature amino acids in the motif, which is consisted of four
and five α-helices in yeast and mammals, respectively (25,30). These helices form a
globular structure, which is required for interactions with various regulatory proteins
(Figure 1.4). The MLLE motif structure is not only found at PABP C-terminus end, but
has also been identified in E3 ligase protein HYD, suggesting the same MLLEinteracting regulatory proteins can be subjected to ubiquitin-mediated protein
degradation (24,30), although there is no evidence so far.
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Figure 1.4 Structure and interaction of PABP C-terminal domain MLLE structure with
PAM2 motif. MLLE domain at the C-terminal end is consisted of five α-helixes (A). MLLE
domain is subjected to mediate the interaction of PABP with PAM2 motif of containing
proteins. The alignment of well-known PAM2 motifs from human PAM2 motif-containing
proteins (B) displays the signature conserved amino acid phenylalanine (red F).
Numbers are assigned based on phenylalanine. The crystal structure of MLLE domain
interacting with PAM2 motif from Paip2 protein is shown (C). Ribbons represent αhelixes 1 to 5 while sticks represent PAM2 motif. Aromatic ring of F118 (red thick arrow)
fitting into the grooves created by α2- and α3-helixes is an indispensable amino acid for
the interaction (crystal structure is adapted with permission license No. 3850620841706
from Kozlov, G., Menade, M., Rosenauer, A., Nguyen, L., and Gehring, K. Molecular
determinants of PAM2 recognition by the MLLE domain of poly(A)-binding protein.
Journal of molecular biology 2010 397, 397-407).
After decades of X-ray crystallography (32) and atomic force microscope (33)
studies, it is now known that those PABPs docking on the mRNA poly(A) tail are in the
same directional arrangement and are oligomerized (31) through the C-terminal domain
of one PABP to neighboring PABP at yet undetermined sites. In this configuration,
although there are several cytoplasmic PABPs docking on the mRNA poly(A) tail, only
the very last one at 3’ end is thought to have an exposed MLLE motif available for

	
  
	
  
	
  

7	
  

	
  
communication (34) with regulatory proteins (PAM2 motif-containing proteins) and 60S
ribosomal subunit (Figure 1.5).
To orchestrate these versatile functions of mRNA poly(A) tail in accordance to
the current model, all the MLLE motif-interacting regulatory proteins must be arranged in
order to interact with the MLLE domain of the last PABP on mRNA tails and be
regulatable in sophisticated ways to respond to the environmental stimuli when
deadenylation rates need to be changed. However, the mechanisms and regulations
underlying these interactions are poorly understood.

Figure 1.5 Current model: MLLE domain of last PABP on poly (A) tail determines which
PAM2 motif-containing proteins to interact with. 5’ cap (green oval) of mature mRNA
(green line) interacts with PABP RRM motif (blue oval) through eIF4E and eIF4G
forming a closed loop structure facilitating translation. All three harboring PABPs are
arranged in the same direction on the poly (A) tail. MLLE domain of each PABP is
oligomerized with neighboring PABP except the last PABP on the very 3’ end of the tail.
This oligomerization is believed to introduce a sterically block preventing 5’Cap structure
to interact with all but the last PABP. All PAM2 motifs (red box) of containing proteins are
regulated to interact with the only MLLE domain on the last PABP at the end of the
poly(A) tail. Through PABP interactions, Pan3, Tob2, and TNRC6 (interacting with
miRNA-Ago2 on the other end of this protein) bring nucleases to the end of the tail to
enhance the poly(A) nuclease processivity.
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1.4 PAM2 motif-containing proteins
The PABP-interacting motif (PAM) was first identified in PABP-interacting protein
1 (Paip1) and PABP-interacting protein 2 (Paip2) proteins (35). The PAM1 motif is an
acidic region comprising ~25 amino acids and PAM2 motif is consisted of 12 conserved
amino acids that interact with the PABP N-terminal RNA-binding motif 2 and PABP Cterminal MLLE motif (36), respectively. In the alignment of the PAM2 motifs from all
eukaryotic proteins, three highly conserved amino acids are identified. Among them,
phenylalanine at position 10 is strictly conserved without exception (Figure 1.4 B). This
phenylalanine is not only a signature feature of the PAM2 motif, but also plays an
indispensable role in MLLE motif interaction (37,38). The aromatic ring of phenylalanine
sterically fits into the groove created by the second and third α-helices of the MLLE motif
(39). Several PAM2 motif-containing proteins have been well studied. For example, by
interacting with PABP, 1) Paip1 can enhance the translation efficiency by interacting with
eIF4A to stabilize circularized mRNA (40); 2) Paip2 can reduce translation efficiency by
competing with the interaction of PABP and eIF4G, causing destabilized circular mRNA
(41); 3) Eukaryotic release factor 3 (eRF3, a GTPase) can facilitate the coupling of
deadenylation to translation termination by cooperating with eRF1 to support GTPdependent translation termination, while providing access point on the poly(A) tail for
deadenylases to work (42,43); 4) Trinucleotide Repeat-Containing Gene 6 (Tnrc6, a
multifunctional scaffold protein in miRNA-mediated gene silencing) can repress
translation by enhancing deadenylation and reducing the PABP-eIF4G interaction. This
leads to diminished translation efficiency, and recruitment of deadenylase complexes to
the end of the poly(A) tail, respectively (44); 5) Pan3 (Poly(A) specific ribonuclease
subunit) can promote deadenylation by recruiting the deadenylase Pan2 to the end of
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the poly(A) tail (17,45); 6) Transducer of ErbB2 (Tob) can enhance deadenylation by
recruiting the deadenylase Caf1 to the end of the poly(A) tail (37,38,45).

1.5 Intrinsically disordered region
Analyzing the crystal structure of the well-studied PAM2 motif-containing proteins
reveals a phenomenon that PAM2 motifs are all located in unstructured regions. This
observation led us to investigate the amino acid composition surrounding PAM2 motifs
by conducting bioinformatics analysis. As will be shown in this dissertation, the PAM2
motifs are embedded in a special region named Intrinsically Disordered Region (IDR)
(45). IDR is a region composed of low amino acid complexity with a high proportion of
hydrophilic polar uncharged amino acids (e.g., serine, threonine, and glutamine) and a
low proportion of hydrophobic amino acids (46-48), which will become the core elements
during globular domain formation. The high flexibility of the IDR region is an important
feature contributing to protein functionality. Due to its constrained properties, the IDR
can easily present an adjacent motif for interaction or post-translational modification, or
the IDR itself can serve as a molecular recognition region controlling proteins interaction.
Furthermore, a coupling of binding and folding is observed in a majority of the IDRs,
which therefore constantly undergo a transition state between unstable (unfolded) and
stable (folded) structure (48). Binding of target protein enables IDR to form a secondary
or tertiary structure, which can further enhance the function of IDR-containing proteins.
The majority of IDR-containing proteins are shown to have promiscuity in terms of target
interactions. Therefore, the IDR can serve as a hub for transducing signals coming from
upstream molecules. For example, tumor suppressor gene P53 can interact with more
than ten targets through its IDR to exert functions (47). That explains well why many
deregulated IDR-containing proteins have been associated with pathogenesis.
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Functions of IDR have been discovered to impact on many cellular events, such
as regulation of transcription and translation, post-translational modification (49), signal
transduction, protein complex assembly, as well as RNA folding (50). Many PAM2 motifcontaining IDR proteins compete for interaction with the MLLE domain of the last PABP
on mRNA poly(A) tail to form messenger ribonucleoproteins (mRNPs) based on the
model that only the last PABP of each transcript is available for PAM2 motif interaction
(34). Judging from the observation that the majority of RNA binding proteins in
interactome have IDRs (51), structural flexibility of IDR surrounding PAM2 motif is
plausible to play a critical role in mRNPs remodeling. Therefore, it is interesting to
investigate the functional role of IDR in PAM2 motif-containing proteins.

1.6 Post-translational modification-phosphorylation
Due to their structure flexibility and promiscuous interactive characteristics,
intrinsically disordered regions are known for their tendency to be post-translationally
modified. Nascent peptides/proteins are modified with all sorts of moieties through
generally enzymatic covalent-linked reactions. Among them, phosphorylation is the most
common and prevalent event. The human kinome accounts for ~2% of genome, which is
one of largest gene families in eukaryotes (52). In estimation of kinase substrates, onethird of proteins in eukaryotic cells are phosphorylated in at least on one site. This
modification is known to regulate a vast range of cellular functions (e.g., cell proliferation,
differentiation, and program-controlled cell deaths at the cellular level; metabolism, DNA
replication/repair, and transcription/translation at the molecular level).
Those functional impacts are most often attributed to phosphorylation-induced
protein conformational change. For example, a phosphorylated site can simply become
a docking site for target proteins. This interaction can facilitate protein shuttling between
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the nucleus and the cytoplasm. In another scenario, a phosphorylated site can promote
conformational change to either reveal or hinder the other modifiable site subjected for
another kinase to act with. This interaction can enable the protein’s function to be
induced or inhibited. In some cases, phosphorylation itself simply provides a negative
charge as a repulsion/attraction force to regulate proteins’ interaction. Due to the
reversible feature of phosphorylation i.e., phosphatases work oppositely on the same
amino acid to remove phosphate group, the effect of phosphorylation can be fine-tuned
accordingly to adapt the cell for different needs.
The intrinsically disordered region is structurally highly flexible, and its
composition is enriched in polar/uncharged amino acid (i.e. serine and threonine). These
properties make it an easily accessed region for post-translational modification and also
a favored region for phosphorylation.

1.7 Significance of this study
This study provides insights into the mechanism of PAM2 motif-containing
proteins-mediated mRNA deadenylation. PAM2 motif-containing proteins are mediators
bringing enzymes to mRNA poly(A) tails. By interacting with a PABP through the PAM2
motif and interacting with nucleases through other motifs, a PAM2-containing protein
enhances the processivity of nucleases on digestion of mRNA poly(A) tail. This
interaction plays critical roles in the cell; however, little is known about the regulation
between PAM2 motif and PABP interaction.
Based on the analysis of intrinsically disordered region in PAM2 motif-containing
proteins and predicted potential phosphorylation site in the same proteins, an interesting
feature is uncovered: PAM2 motifs, required for PABP interaction, are not only
embedded in the intrinsically disordered region but also adjacent to a cluster of potential
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phosphorylation sites. Therefore, phosphorylation in the intrinsically disordered region of
a PAM2 motif-containing protein may regulate the interaction between PAM2 motif and
MLLE domain of PABP, leading to change in deadenylation rates.
To test the hypothesis, the work described in Chapter 3 examines whether
induction or reduction of phosphorylation status of PAM2 motif-containing proteins by
Calyculin A or phosphatase, respectively, regulates their interaction with PABP but not
the interaction with nucleases away from PAM2 motif. I found that, in general, the less
the phosphorylation of PAM2 motif-containing proteins, the more PABPs it can pull
down, and vice versa. The work in Chapter 3 also tested the idea that potential
phosphorylation sites in PAM2 motif-containing proteins diminish the Tob2 and Pan3
functions in deadenylation enhancement and the TNRC6c function in gene silencing. My
findings open up a new direction for RNA researchers to investigate the role of
phosphorylation in all PAM2 motif-containing proteins-mediated biological functions.
The work described in Chapter 4 examines our hypothesis further by pinpointing
the real phosphorylated sites and the kinases involved. Mass spectrometry results
indicate that c-JUN N-terminal kinase (JNK) can induce phosphorylation of multiple sites
in the intrinsically disordered region of Tob2, supporting our finding that the higher the
Tob2 phosphorylation induced by JNK1, the less PABP the Tob2 can pull down. This
phenomenon confirms the hypothesis proposed in Chapter 3. On the way to identify the
most critical phosphorylation site induced by JNK1, one serine inside second PAM2
motif (S245) was found to play a pivotal role in Tob2 functions. The phosphorylation at
S254 significantly enhances the Tob2 ability to interact with PABP and may link to
enhancing the deadenylation rates of global mRNA.
The effect of Tob2 S254D on PABP interaction is through synergism of the two
PAM2 motifs. When S254 is in non-phosphorylation status, only first PAM2 motif is

	
  
	
  
	
  

13	
  

	
  
interacting with PABP. Phosphorylation at S254 not only enables both PAM2 motifs to
greatly associate with PABP, but also gives the second PAM2 motifs more affinity
toward the PABP than the first one. Based on these observations, a model for the
regulation of deadenylation by changing the phosphorylation status of Tob2 was
proposed (see Chapter 4).
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Chapter 2
Materials and methods
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2.1 Plasmids construction
The plasmids myc-PABPC1, HA-Pan3, HA-Tnrc6, λN-HA-LacZ, Tob2-V5, MS2Tob2-V5, Paip1-V5, and Caf1-V5 were constructed previously (16,37,38,44,54).
Constitutive-activated JNK plasmid Flag-MKK7B2-JNK1a1 (Addgene plasmid # 19726)
was a gift from Dr. Roger Davis. In-Fusion approach was used to clone Tob2-V5 (WT,
S254A, S254D) into pLVX-tight-puro tetracycline-inducible lentivirus expression vector
(Clontech) using the In-Fusion kit (Clontech) according to the manufacturer’s protocol.
The extra 15 nucleotides sequence that matched to both ends of BamHI and EcoRI cut
lentivirus vector were synthesized after 3’ end of the primers that flanked the complete
Tob2-V5. PCR amplified Tob2-V5 carrying homologous sequence recombined with
enzyme-linearized vector.
(Below is an excerpt from “phosphorylation at intrinsically disordered regions
of PAM2 motif-containing proteins modulates their interactions with PABPC1 and
influences mRNA fate. KAI-LIEH HUANG, AMANDA B. CHADEE, CHYI-YING A. CHEN,
YUEQIANG ZHANG, and ANN-BIN SHYU RNA. 2013 Mar;19(3):295-305. doi:
10.1261/rna.037317.112.”)
To generate pcDNA6-eRF3b-V5, mRNA from human testis was reversetranscribed into cDNA. The gene was then amplified using specific primers (5′ TGGAATTCTGCAGATACCATGGATTCGGGCAGCA GC-3′ and 5′ GCCACTGTGCTGGATTGTCCTTCTCTGGGACC AAT-3′) and subcloned into the
EcoRV-linearized pcDNA6-V5 vector. To construct phosphomimetic (PM, Ser/Thr →
Asp/Glu) mutants and nonphospho (NP, Ser/Thr → Ala) mutants of Tob2, Pan3, and
Tnrc6c, minigene fragments spanning the targeted area of proteins with multiple
mutations (Figure 3.5) were synthesized by IDT and Invitrogen. The In-fusion kit
(Clontech) was used to replace the targeted regions in wild-type expression
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constructs with the minigenes, following the manufacturer’s manual. DNA sequencing
was performed to confirm all the desired mutations and in-frame fusions.

2.2 PCR-based site-directed mutagenesis
PCR reaction was carried out to create plasmids bearing the mutation. 25 ng of
template plasmid is added into total volume of 50µl reaction containing 10uM forward
and reverse primers (sequence are listed below), 10mM dNTP, 5 units of Pfu DNA
polymerase, and 1X reaction buffer. A negative control reaction, replacing Pfu with
water, was set side by side. Amplification is set first at 95°C for 1min, second at 18
cycles of 95°C for 30sec, 55°C for 60sec, and 68°C for 1min/1kb long plasmid, third at
68°C for 10min, and last at 12°C forever. This was followed by 40 units DpnI (NEB)
direct treatment in 37°C for 4hr, to eliminate the template plasmid, and 1µl was taken
from the reaction for transformation using TOP 10 high efficient competent cells
(Invitrogen). The difference of growing colonies between the experiment and the control
has to be 10X higher to assure successful following check-up. Selected colonies were
subjected to size diagnosis by restriction enzymes, DNA sequencing, and protein overexpression in cells to confirm identity.
Tob2 F260A F

5’-CCCAATGCCAAGGAGGCCGTGTACAACGGTGGT-3’

Tob2 F260A R

5’-ACCACCGTTGTACACGGCCTCCTTGGCATTGGG-3’

Tob2 F140A F

5’-CCTGACGCCCAGGTGGCCGTGCCCATTGGCAGC-3’

Tob2 F140A R

5’-GCTGCCAATGGGCACGGCCACCTGGGCGTCAGG-3’

Tob2 S254A F

5’-CCTCAGTCCCAGCTCGCACCCAATGCCAAGGAG-3’

Tob2 S254A R

5’-CTCCTTGGCATTGGGTGCGAGCTGGGACTGAGG-3’

Tob2 S254D F

5’-CCTCAGTCCCAGCTCGATCCCAATGCCAAGGAG-3’

Tob2 S254D R

5’-CTCCTTGGCATTGGGATCGAGCTGGGACTGAGG-3’
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Tob2 S222A F

5’-CCTCGCATGGCCCGCGCACCCACCAACAGCCTG-3’

Tob2 S222A R

5’-CAGGCTGTTGGTGGGTGCGCGGGCCATGCGAGG-3’

Tob2 S222D F

5’-CCTCGCATGGCCCGCGACCCCACCAACAGCCTG-3’

Tob2 S222D R

5’-CAGGCTGTTGGTGGGGTCGCGGGCCATGCGAGG-3’

Tob2 S117A F

5'-CTGTACCTGGATGACGCCGAGGGTTGCGGTGCC-3’

Tob2 S117A R

5'-GGCACCGCAACCCTCGGCGTCATCCAGGTACAG-3’

Tob2 S117D F

5'-CTGTACCTGGATGACGACGAGGGTTGCGGTGCC-3’

Tob2 S117D R

5'-GGCACCGCAACCCTCGTCGTCATCCAGGTACAG-3’

Tob2 S119A F

5'-GGGGGCGGGGCAGCAGCCGGTGGGGGTGTAGCC-3’

Tob2 S119A R

5'-GGCTACACCCCCACCGGCTGCTGCCCCGCCCCC-3’

Tob2 S119D F

5'-GGGGGCGGGGCAGCAGACGGTGGGGGTGTAGCC-3’

Tob2 S119D R

5'-GGCTACACCCCCACCGTCTGCTGCCCCGCCCCC-3’

Tob2 T224A S226A F

5'-ATGGCCCGCTCACCCGCCAACGCCCTGCTGAAGCACAAG-3’

Tob2 T224A S226A R

5'-CTTGTGCTTCAGCAGGGCGTTGGCGGGTGAGCGGGCCAT-3’

Tob2 T224E S226D F

5'-ATGGCCCGCTCACCCGAGAACGACCTGCTGAAGCACAAG-3’

Tob2 T224E S226D R

5'-CTTGTGCTTCAGCAGGTCGTTCTCGGGTGAGCGGGCCAT-3’

Tob2 S232A F

5'-CTGCTGAAGCACAAGGCCCTCTCTCTGTCTATG-3’

Tob2 S232A R

5'-CATAGACAGAGAGAGGGCCTTGTGCTTCAGCAG-3’

Tob2 S232D F

5'-CTGCTGAAGCACAAGGACCTCTCTCTGTCTATG-3’

Tob2 S232D R

5'-CATAGACAGAGAGAGGTCCTTGTGCTTCAGCAG-3’

Tob2 T244A F

5'-TCACTGAACTTCATCGCCGCCAACCCGGCCCCT-3’

Tob2 T244A R

5'-AGGGGCCGGGTTGGCGGCGATGAAGTTCAGTGA-3’

Tob2 T244E F

5'-TCACTGAACTTCATCGAGGCCAACCCGGCCCCT-3’

Tob2 T244E R

5'-AGGGGCCGGGTTGGCCTCGATGAAGTTCAGTGA-3’

Tob2 S251A F

5'-AACCCGGCCCCTCAGGCCCAGCTCTCACCCAAT-3’
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Tob2 S251A R

5'-ATTGGGTGAGAGCTGGGCCTGAGGGGCCGGGTT-3’

Tob2 S251D F

5'-AACCCGGCCCCTCAGGACCAGCTCTCACCCAAT-3’

Tob2 S251D R

5'-ATTGGGTGAGAGCTGGTCCTGAGGGGCCGGGTT-3’

2.3 Cell culture, transfection, and protein induction
U2OS and 293T cells are cultured in DMEM high glucose (Invitrogen) containing
10% fetal bovine serum (Invitrogen) and 1x penicillin/streptomycin/glutamine (Gibco).
NIH3T3 and B2A2 cells (Shyu et al. 1998) are cultured in the DMEM high glucose
containing 10% calf serum (Invitrogen) and 1x penicillin/streptomycin/glutamine
(Invitrogen). 500ng/ml tetracycline (Sigma) and 200 ng/ml of doxycycline (Sigma) are
added in culture medium for maintaining B2A2 cell and stable cloned Tob2-V5 inducible
U2OS cell, respectively. 5% CO2 is provided in 37°C incubator for cells to grow.
Transfection is performed in reverse fashion. Briefly, Opti-MEM I Reduced Serum
Medium (Invitrogen) is used to dilute plasmids and Lipofectamine 2000 (Invitrogen) in
separate tubes. The ratio of plasmid to Lipofectamine 2000 is kept at 1µg to 3µl. Each
10cm dish of cells is transfected with 18µg of plasmids DNA including 6µg Tob2
expression plasmid and 12µg carrier plasmid. After 5min RT incubation of dilution,
diluted plasmids are mixed with diluted Lipofectamine 2000 thoroughly, and kept another
20min for complexes to form. In the meanwhile, cells number that will make 60%
confluence of dish once attached are seeded. Mixture is directly added into the just
seeded cells. Cells are ready for analysis after 1-day incubation.
To screen the kinases, Tob2-overexpressed cells are pretreated with various
kinase inhibitors U0126 (Selleckchem), SB203580 (Selleckchem), SP600125
(Selleckchem), LY294002 (Selleckchem), SB216763 (Selleckchem), Rapamycin
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(Selleckchem), SL0101 (Calbiochem), and Akt inhibitor IV (Calbiochem) before Calyculin
A (Cell Signaling) treatment.
To measure the kinetics of default deadenylation, transcriptional pulse strategy
was used by delivering reporter gene plasmid under the control of inducible promoter
into mammalian cell and allowing a short period of time for transcription before harvest
RNA in time course to monitor shortening of mRNA poly(A) tail and decaying of mRNA
body (13). To induce cells to express transient transfected β-globin reporter gene and
stable cloned Tob2-V5 genes, cells were grown in the reduced 50ng/ml tetracycline or
Doxycycline-containing medium, one night before induction. On the day of induction,
cells were washed twice with RT PBS followed by another two washes with the culture
medium containing tetracycline-free FBS (Clontech) and 1x
penicillin/streptomycin/glutamine. Cells were grown in the culture medium used for wash
for specific times, 24hr for co-IP, Northern blot, and poly (A) size distribution assays;
10hr for pulse-chasing bromouridine metabolic RNA labeling assay.

2.4 Stable cell lines establishment
To establish tetracycline-controlled transactivator (tTA) expressing stable U2OS
cell line and following Tob2-V5 Tet-off inducible U2OS cell line, lentivirus system, Lenti-X
Tet-off Advanced Inducible Expression System (Clontech), was adopted to produce the
viruses carrying gene of interest. Briefly, for tTA-U2OS cell establishment, 1.5 x 107
293T cells were reverse transfected with 24µg in total pLVX-Tet-off advance (Clontech),
psPAX2 (a gift from Dr. Didier Trono, Addgene plasmid # 12260), and pMD2.G (a gift
from Dr. Didier Trono, Addgene plasmid # 12259) plasmids in the ratio of 3 : 2 : 1 in
10cm dish using Lipofectamine 2000. Change to fresh medium 8hr after transfection.
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Virus-containing medium was harvested 3 times after 32, 48, and 56 hr of transfection by
collecting the medium in 50ml tube and replacing fresh medium back.
Cell debris was removed immediately by spinning at 500g for 10min in 4°C. The
virus-containing medium was kept at a temperature of 4°C while waiting for later time
point virus medium. Concentration of virus particles was necessary to enhance
transduction efficiency by mixing 3 part of virus medium with 1 part of Lenti-X
concentrator (Clontech) prior overnight 4°C incubation to spin down virus pellet by
centrifuge the tube for 45min in 4°C. The virus pellet was resuspended with 1/40th of
original volume of medium containing polybrene (Santa Cruz) at final concentration of
10µg/ml. U2OS cells seeded in 12-well plate were infected by replacing growth medium
with virus medium for a day. The infected cell population were expanded for a period of
10 days while doing selection by adding 400µg/ml G418 (ThermoFisher) and 50ng/ml
Doxycycline (Sigma). In order to pick single colony, cells were split and 50 of the cells
were seeded in 10cm dish following another 10 days to let single cells grow into visible
colonies. Cloning cylinders (Corning) combined with vacuum grease (Corning) and
trypsin was used to collect single colonies. From the 48 picked colonies, U2OS clone29
were selected depending on the inducibility test.
U2OS clone29 cell is used as a parental cell for establishing of Tob2-V5
inducible stable cell lines. In brief, lentivirus is produced by transient transfection of
lentivirus expression vector pLVX-tight-puro (Clontech) carrying Tob2-V5 gene and
packaging plasmids into 293T. The harvested virus-containing medium was
concentrated before adding onto the cell culture. After 1 day of transduction, a selection
culture medium (10% FBS, 1x penicillin/streptomycin/glutamine, 400µg/ml G418,
200ng/ml Doxycycline, 5µg/ml puromycin) was used for total 48hr of incubation to kill
non-infected cells. Parental U2OS clone29 cell was grown side by side during the
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selection period to serve as negative control. Puromycin and G418 were removed from
medium for continuing cell culture after the selection period.

2.5 Proliferation assay
CyQUANT Cell Proliferation Kit (Invitrogen) was used to detect the amount of
DNA in each well of plate to represent the cell number in that well. Briefly, 1 x 103 cells
were seeded in each of 96-well black-well clear-flat-bottom plate (Corning) supplied with
100µl of medium. Harvest plates were used each day for the course of 5 days by pouring
out the medium and draining the remaining on paper towels before freezing the plates in
-80°C waiting for all time points of plates were collected. The plates were thawed in RT
under low light environment, adding 200µl 1X cell lysis buffer containing CyQUANT GR
dye working solution into each well and incubated for 5 min with shaking before
measuring the fluorescent on the Infinite 200 PRO plate reader (Tecan) with 480nm
excitations and 520nm emissions.

2.6 Cell cycle analysis
A 10cm dish of ~50% confluent cells (2~3 x 106) were harvested by
trypsinization, followed by neutralization with cold medium in 15ml tube. The cells were
washed twice with 10ml cold PBS, and resuspend in 0.5ml PBS. To fix the cells, the tube
was vortexed gently while adding 5ml of cold 75% EtOH drop by drop into the tube. This
was incubated in 4°C overnight, and then moved to -20°C for temporary storage to wait
for all time course samples to be collected. Propidium iodide (Invitrogen) was used to
stain the chromosomes. In brief, cells were spun down at 600g for 5min prior to the two
cold PBS washes. All supernatants were carefully removed and cells were resuspended
in 400µl PI staining solution (40µg/ml propidium iodide, 200µg/ml RNase A and 0.1%
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Triton X-100 in 1X PBS). This was incubated in 37°C for 30min for RNase A to work.
During the incubation, the tubes were agitated every 10min to assure homogeneous
penetration of RNase A into cells. The tubes were kept on ice while transferring cells into
filtered-top flow cytometry tubes (BD Biosciences). The fluorescent intensity in each cell
was detected on the BD FACSCalibur and followed by data analysis using FlowJo
software. Watson cell cycle model was applied to each analysis result to avoid phase
distribution assignment bias.

2.7 Co-immunoprecipitation and western blot
One 10cm dish of cells (~5 x 106) was washed twice with cold PBS on ice before
scraping down into 1.5ml tube with 1ml of cold PBS. The cells were spun down and
lysed in 900µl of co-IP lysis buffer (50mM Tris pH7.4, 150mM NaCl, 0.4% NP-40, 1mM
EGTA, and 10% glycerol) with protease and phosphatase inhibitors (2mM sodium
orthovanadate, 2mM sodium pyrophosphate, 10mM sodium fluoride, 1mM
phenylmethylsulfonyl fluoride, 1x complete Protease inhibitor from Roche, 1x
phosphatase inhibitor cocktail 3 from Sigma). RNase A (Sigma) 200µg was added into
each tube and incubated in 4°C with rotation for 1hr to digest RNA. After removing the
debris with 12,000g 15min spinning, the supernatant was collected and the
concentration with BCA reagent (Bio-Rad) was measured. The concentration of each
sample was adjusted to the same with cold lysis buffer. An equal volume of lysate was
subjected for co-IP. One-tenths of the volume was saved for input protein level
examination. To pull down V5-tagged protein, an anti-V5 agarose affinity beads (Sigma)
was used. Briefly, 50µl 50% slurry beads were washed three times with cold lysis buffer
for each dish of cells. All wash buffers were discarded before adding lysate and
incubated at 4°C with rotation for 2hr. The beads were spun down with 500g for 3min,
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and the supernatant was removed. The beads were then washed with 1ml cold lysis
buffer for 3min. The washing process was repeated for a total of five times. The buffer
above the beads was removed as much as possible by using 31G needle attached to
the suction. The beads were boiled in 50µl 1x Laemmli Sample Buffer (Bio-Rad) for 5min
to release and denature co-immunoprecipitated proteins. In order to obtain well-resolved
Tob2 phosphorylation pattern, 7.5% polyacrylamide denature gel was prepared. Twothirds of the samples were running at 80V till the bromophenol blue dye front
disappeared. Proteins in the gel were transferred to PVDF membrane (Millipore) using a
semi-dry system running at 20V for 20min. The membrane was first soaked in blocking
buffer (5% non-fat milk in 1xPBS with 0.1% tween-20) for 1hr, then changed to the
blocking buffer containing diluted antibody in the following ratios: 1:2000 for rabbit antiPABP (RRM4) antibody (a gift from Dr. Richard E. Lloyd); 1:2000 for rabbit anti-Caf1
antibody (16); 1:2500 for mouse anti-V5-HRP conjugated antibody (Invitrogen); 1:2000
for rabbit anti-Flag antibody (Sigma); 1:1000 for rabbit anti-JNK antibody and for rabbit
anti-phospho-JNK (Thr183/Tyr185) antibody (Cell Signaling); 1:1000 for rabbit antiGAPDH-HRP conjugated antibody (Santa Cruz). After overnight incubation with gentle
shaking in 4°C followed by three times 5min wash in PBST, the membrane was now
either ready for signal development if primary antibody had HRP conjugated or ready for
secondary antibody detection. The ratio 1:5000 was applied to dilute HRP-conjugated
anti-mouse or anti-rabbit secondary antibodies (Bethyl) in blocking buffer. After 1hr
incubation with the secondary antibody followed by three times 5min wash, the
membrane was ready for signal development. SuperSignal West Pico chemiluminescent
solution (Thermo) was applied on the membrane and stood for 5min before exposure.
Signals were captured by GeneGnome (Syngene) and quantified by GeneSnap
(Syngene) software.
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2.8 RNA preparation and RNA-immunoprecipitation
Cytoplasmic RNA was extracted from cell using RNeasy Mini Kit (Qiagen) and
following the manufacturer’s manual. In brief, cell pellet collected from 10cm dish of cells
was lysed with 180µl RLN buffer (50mM Tris pH8.0, 1.5mM MgCl2, 140mM NaCl, 0.5%
NP-40, 1X complete EDTA-free Protease Inhibitor from Roche, and 1X phosphatase
inhibitor cocktail 3 from Sigma). Debris was removed by spinning at 500g for 5min
before collecting cytoplasmic fraction. The collected 170µl of the solution was mixed with
600µl RLT/b-ME with vigorous vortexing. RNA was precipitated by adding 430µl 100%
RT EtOH. The mixture was passed through the mini column and the column was
washed with RW1 buffer. To ensure pure RNA extraction with DNA contamination, oncolumn DNase I (Qiagen) treatment was carried out for 1hr in RT. The column was
washed with RW1 buffer again followed by several times of washes with RPE wash
buffer. The column was dried by centrifugation and RNA was eluted with ddH2O to make
concentration around 1µg/µl empirically. The concentration was measured using
NANODROP LITE (Thermo).
For RNA-immunoprecipitation, samples were first adjusted to the same
concentration with ddH2O. Equal amount of RNA was used as input for precipitation. In
order to have 1µg of bromouridine-labeled RNA, about 100µg of total RNA was required
to start with. To prepare the beads for 100µg RNA pull down, 150µl Dynabeads Protein
G (Invitrogen) was first washed with cold WASH/IP buffer (0.1% BSA and 0.02% Triton
X-100 in 1X PBS) 3 times. The beads were restored to their original volume with
WASH/IP buffer before adding 12µg mouse anti-BrdU clone 3D4 antibody (BD
Biosciences). The mixture was rotated in 4°C overnight followed by washing it 4 times
with cold WASH/IP buffer. The antibody-conjugated beads were resuspended to the
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volume that was equal to the volume of input RNA with WASH/IP buffer in order to
control the concentration of RNA and keep it consistent 0.5µg/µl between samples and
experiments. RNase out (Invitrogen) was added into the resuspended beads to have
final concentration of 1 unit/µl. Total RNA was added onto the beads and incubated on
rotator in 4°C for 4hr. This was washed 5 times thoroughly with cold WASH/IP buffer,
and the beads were moved to a new tube during the last wash. The bromouridinelabeled RNA was eluted from the beads using RNeasy Mini Kit (Qiagen) RNA clean-up
manufacture’s protocol. To obtain accurate pull down RNA concentration, Quant-iT
RiboGreen RNA Assay Kit (Thermo) was used.

2.9 Sample preparation for RNA sequencing
Confluent cells at ~70% were prepared in a dish ready on the day of labeling.
Half of the medium was collected from the dish, and 200mM bromouridine (Sigma) stock
was added into the medium to make a final 10mM concentration. The rest of the medium
was collected from the dish for later uridine chasing purpose. Working bromouridine
medium was added back to the dish, and incubated at 37°C with 5% CO2 for 2hr.
Meanwhile, 2M uridine stock was added into the other half of medium to make a final
20mM concentration. Right after 2hr incubation, bromouridine-containing medium was
replaced with uridine-containing medium, and the cell was harvested using trypsin
method in the time course manner. Cell pellet was washed twice with cold-PBS before
RNA extraction. Removal of rRNA contamination was conducted using Ribo-Zero Gold
beads. Cleaned-up RNA was fragmented into average 155bp by heating. Double strand
blunt end cDNA was synthesized and repaired. Adenosine was added to 3’ end of each
cDNA followed by ligation with barcoded adaptor. cDNA pool went through 15 cycles of
amplification to enrich those DNA fragment that have adaptors at both ends. Library
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validation was running on Agilent DNA 1000 chip (Agilent) to confirm the size of library
was around 260bp. RNA sequencing was conducted (LC Sciences, Houston TX) on
Illumina Hi-Seq 2000 with 2 x 100bp paired-end sequencing run.

2.10 Northern blot
To detect changes of size and amount of specific RNA (ranged around 500bp),
8µg of total cytoplasmic RNA was subjected to electrophoresis on 1.4% agarose gel (1X
MOPS buffer, 7.5% formaldehyde solution, and 0.2µg/ml EtBr). Briefly, RNA sample was
first dried in Speedvac concentrator followed by dissolution in denature buffer (134µl
deionized formamide, 40µl 37% formaldehyde solution, 18µl 20X MPOS, and H2O to
250µl total volume). Denature was carried out for 15min in 65°C water bath and chilled
on ice. 4X loading dye (50% sucrose and 0.2% bromophenol blue) was mixed with
sample before running on the gel overnight with consistent 60V. The gel was washed
thoroughly in H2O and 10X SSC buffer before transferring the RNA onto GeneScreen
membrane (PerkinElmer) for blotting. RNA was fixed on the membrane with 120,000uJ
UV, and the membrane was blocked with ULTRAhyb hybridization buffer (Thermo) for
2hr in 42°C oven. Gene specific isotope-labeled probe was generated using Rediprime II
random primer labeling system (Amersham). To detect β-globin, 25 ng of probe was
mixed with 5µl of 6,000 Ci/mmol [a-32P]-dCTP (Perkin-Elmer) in the reaction, and
incubated for 1hr at 37°C. To remove free [a-32P]-dCTP, the probe was purified through
illustra MicroSpin G-25 column (GE Healthcare). After TCA precipitation, scintillation
counter calculation, and heat denaturation, 1x105 cpm/ml probe was added into
hybridization reaction for overnight incubation at 42°C. The membrane was washed
thoroughly with three buffers several times (2X SSC/0.1%SDS, 0.1XSSC/1%SDS, and
0.1XSSC) in order before exposure. To generate poly(A)- RNA for negative control use
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purpose, total RNA was mixed with oligo (dT)12~18 primer followed by RNase H
treatment. Decay profile was plotted using ImageJ (NIH) software. All experiments were
repeated at least twice with reproducible results.

2.11 Poly (A) tail distribution assay
To measure tail length of total mRNA population, 3’ end of each tail has to be
labeled with isotope before digestion of the non-poly (A) part of mRNA with RNases.
Resolving this pure tail sample provides the information of tail length distribution of
whole mRNA population. Briefly, 3µg of total RNA was subjected to 3’ end tail labeling
with [a-32P]-dATP in the reaction containing 1X poly (A) polymerase buffer, 600 units
poly (A) polymerase (Affymetrix), 20 units RNase inhibitor, and 10uCi [a-32P]-dATP. DNA
ladder (Invitrogen) was labeled with the same isotope in the reaction (1X terminal
transferase buffer, 0.8 units/µl terminal transferase, 0.25mM CoCl2, 1.5µg DNA ladder,
and 10uCi [a-32P]-dATP) side by side. This was incubated in 37°C water bath for 1hr
before removal of free isotope following RNeasy Mini Kit (Qiagen) RNA clean-up
manufacture’s protocol. 20 ng RNase A (Sigma) and 100 units of RNase T1 (Sigma)
were mixed in the 20µl digestion buffer (62.5mM Tris pH7.4, 250mM KCl, 12.5mM EDTA
pH8, and 2µg/µl yeast RNA), and added into eluted 30µl RNA for exactly 30min in 37°C
incubation. 2X stop buffer (200mM Tris pH7.4, 25mM EDTA pH8, 2% SDS, 0.8µg/µl
proteinase K, and 0.2µg/µl Glycogen) was added followed by another 30min in 37°C
incubation. After phenol/chloroform extraction, EtOH precipitation, TCA precipitation, and
scintillation counter calculation, equal amounts of 20,000cpm isotope-labeled RNA
samples were denatured in 2X formamide loading dye (Deionized formamide, 10mM
EDTA pH8, 1mg/ml bromophenol blue, and 1mg/ml xylene) and loaded onto denaturing
8% polyacrylamide (Acrylamide:Bis=19:1) urea (7M) gel. The gel was dried with Gel
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Drying Kit (Promega) overnight, and exposed. The profile of poly (A) tail distribution was
plotted using ImageJ (NIH) software.

2.12 Sample preparation for Mass spectrometry
To reach lowest non-specific background signal, co-immunoprecipitation method
was modified accordingly for this analysis. In brief, cells were lysed in special co-IP lysis
buffer (50mM Tris pH7.4, 150mM NaCl, 1% NP-40, 1mM EGTA, 10% glycerol, and 2%
BSA) with protease and phosphatase inhibitors (2mM sodium orthovanadate, 2mM
sodium pyrophosphate, 10mM sodium fluoride, 1mM phenylmethylsulfonyl fluoride, 1x
complete Protease inhibitor from Roche, 1x phosphatase inhibitor cocktail 3 from
Sigma). RNA was digested with RNase A (Sigma) before centrifugation to remove
cellular debris. The concentration of lysate was then adjusted to 0.5µg/µl to avoid the
chance of non-specific binding. The lysate was ready for pull down after pre-cleaning
with non-relevant anti-HA agarose beads (sigma). Anti-V5 agarose beads (Sigma) were
pre-blocked with the special co-IP lysis buffer overnight before adding into lysate. After
thorough washes, Tob2-V5 was eluted with V5 peptide elution buffer (0.4mg/ml V5
peptide from Sigma, 25mM Tris pH7.4, 100mM NaCl, and 0.05% Triton X-100). The
eluted solution was then concentrated by passing through 10 KD cut-off centrifugal filter
column (Amicon). Silver staining (Bio-Rad) was performed to ensure specificity by
comparing the gels between Tob2-V5 and Vector –expressing cell lysate. Gel bands
were analyzed by microcapillary LC/MS/MS (Taplin Mass Spectrometry Facility, Harvard
Medical School).
2.13 Renilla and firefly dual luciferase assay
(An excerpt from “Phosphorylation at intrinsically disordered regions of PAM2
motif-containing proteins modulates their interactions with PABPC1 and influences
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mRNA fate. KAI-LIEH HUANG, AMANDA B. CHADEE, CHYI-YING A. CHEN,
YUEQIANG ZHANG, and ANN-BIN SHYU RNA. 2013 Mar;19(3):295-305. doi:
10.1261/rna.037317.112.”)
U2OS cells were transiently transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Briefly, 0.6 × 106 of U2OS cells were
seeded in six-well plates before addition of 20 ng of the reporter plasmid (psi-check2 or
psi-check2-4xboxB) and 3 ug of pcDNA-λN-HA-lacZ, pcDNA-λN-HA-TNRC6C (WT or
mutant). Cells were harvested 42 h after transfection, and samples were analyzed
simultaneously for firefly and Renilla luciferase activities using the Dual-Glo Luciferase
Assay System (Promega) according to the manufacturer’s instructions. The relative
levels of Renilla luciferase activity were normalized by dividing each reporter’s Renilla
luciferase activity by its firefly luciferase control.
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Chapter 3
Phosphorylation of intrinsically disordered region
of PAM2 motif-containing proteins
modulates their interaction with PABP and
influences mRNA fate

This chapter is reprinted with permission from
Huang, K. L., Chadee, A. B., Chen, C. Y., Zhang, Y., and Shyu, A. B.
Phosphorylation at intrinsically disordered regions of PAM2 motif-containing proteins
modulates their interactions with PABPC1 and influences mRNA fate.
RNA. 2013 Mar; 19(3): 295–305.
doi: 10.1261/rna.037317.112.
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Introduction
Mammalian cytoplasmic poly(A)-binding protein (PABP) C1 is a highly conserved
and abundant RNA-binding protein that binds to the 3′ poly(A) tails of mRNAs and has
several roles in controlling the cytoplasmic fate of mRNA(24,55). In the cytoplasm,
PABPC1 proteins in complex with mRNA 3′ poly(A) tails facilitate formation of the
“closed-loop” structure of the mRNA-ribonucleoprotein particle (mRNP) (56). This
closed-loop mRNP structure helps enhance translation initiation and termination,
promote recycling of ribosomes, and influence the stability of the mRNA (19,57-59). In
these cytoplasmic processes, PABPC1 serves as a binding scaffold for other proteins
involved in translation regulation and mRNA turnover. The recent discovery that
interactions of GW182/Tnrc6 proteins with PABPC1 are critical for miRNA-mediated
gene silencing (60) further highlights the importance of studying the actions of
interactions between PABPC1 and its partners for understanding the post-transcriptional
control of gene expression.
Among mammalian PABPC1-interacting proteins, at least 16 contain the motif of
∼12 amino acids termed the PABP-interacting Motif 2 (PAM2) (36,60). Structural data
show that the PAM2 motif binds to the highly conserved MLLE domain in the C-terminal
region of PABPC1 (30,42,61). Among the PAM2- containing proteins are several wellstudied translation and mRNA decay factors, including PAIP1 (35), PAIP2 (62), Tnrc6
(63), Eukaryotic peptide chain release factor 3 (eRF3) (31), PABP-dependent poly(A)
nuclease subunit 3 (Pan3) (64), and transducer of erbB-2 proteins (Tob) (65). The
number of PAM2- containing proteins and their varied roles in mRNA metabolism
suggest several important questions. For example, how does the cell regulate
interactions between PABPC1 and its binding partners to respond to different biological
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processes? What molecular mechanism controls association and dissociation between
PABPC1 and individual binding partners?
In view of the observation that PAM2 motifs appear to occur outside globular
protein domains (36), we hypothesized that PAM2 motifs primarily reside in intrinsically
disordered or unstructured regions (IDRs). IDRs can retain significant regions of disorder
under physiological conditions, even when positioned near one or more structured
domains (46,47,66). Interestingly, a recent study of mRNA interactomes found that
proteins associated with mRNAs are highly enriched in IDRs compared to the human
proteome overall (51). The dynamic nature of IDRs combines structural flexibility with a
high functional density and multiple interaction interfaces (48,50,67). The major functions
currently ascribed to disordered regions are protein–protein binding, protein–DNA/RNA
binding, and substrate–ligand binding. Therefore, this region serves as a good target for
posttranslational modification-phosphorylation (48,50,67).
Reversible protein phosphorylation provides a key regulatory mechanism for a
plethora of signal transduction processes in eukaryotic cells (68-70). Most
phosphorylation occurs at serine or threonine residues (71,72). One characteristic
feature of disordered segments is an enrichment in polar, uncharged amino acids such
as serine and threonine (49). It has also been noted that the amino acid composition,
sequence complexity, hydrophobicity, and charge of regions adjacent to phosphorylation
sites resemble those of IDRs (49,73). Based on these observations, IDRs are predicted
to be “hotspots” for protein phosphorylation(49).
We have conducted a bioinformatics analysis of thirteen human PAM2-containing
proteins and found that, with the exception of eRF3b, the PAM2 motif is embedded in an
extended IDR and is close to a cluster or clusters of potential Ser/Thr phosphorylation
sites. We hypothesized that reversible phosphorylation of these Ser/Thr clusters is
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required for modulating interactions between the PAM2-containing protein and PABPC1,
thereby controlling mRNA fate. To test this hypothesis, in this study we used
complementary approaches to change the phosphorylation states of three representative
PAM2-containing proteins and determine the corresponding functional consequences.
The experimental results not only support our hypothesis but also provide a new
framework for designing future studies to investigate how the many distinct mRNA
functions involving PABPC1 and its PAM2-containing interacting partners may be
regulated and coordinated in eukaryotic cells.

Results
3.1 PAM2 motifs are generally embedded within intrinsically disordered
regions. As PAM2 motifs in general occur in protein regions that seem not to assume
any known structure (36), we used two online tools, “PONDR” and “Globplot,” to identify
candidate IDRs within 13 human MLLE domain-interacting, or PAM2-containing, proteins
(Table 3.1). PONDR analysis predicts regions that are not rigid (including random coils,
partially unstructured regions, and molten globules) based on local amino acid
composition, flexibility, and hydropathy (74,75). The Globplot predicts regions with a high
propensity for globularity on the Russell/ Linding scale (propensities for secondary
structures and random coils) (76). Analyses done by PONDR predict that all PAM2containing proteins examined have an extensive IDR, with eRF3b predicted to be ∼25%
IDR and the others predicted to be >32% IDR (Table 3.1). Moreover, the PAM2 motifs in
these proteins re-side within the predicted IDRs (see representative examples
schematically shown in Figure 3.2).
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Protein
Pan3 (PAN3_HUMAN, Q58A45)
Tob1 (TOB1_HUMAN, P50616)

Cellular function
mRNA decay. Recruites Pan2 deadenylase.

Amino acid
length

86-102

PAM2 motif

36

% Disorder

34

687
345

TNRC6c (TNR6C_HUMAN, Q9HCJ0)

TNRC6b (TNR6B_HUMAN, Q9UPQ9)

TNRC6a (TNR6A_HUMAN, Q8NDV7)

eRF3b (ERF3B_HUMAN, Q8IYD1)

Coactivator in translation initiation and mRNA decay.

miRNA-mediated gene silencing. Interacts with Ago proteins
and recruits Pan2-3 and Caf1-Ccr4 deadenylases.

miRNA-mediated gene silencing. Interacts with Ago proteins
and recruits Pan2-3 and Caf1-Ccr4 deadenylases.

miRNA-mediated gene silencing. Interacts with Ago proteins
and recruits Pan2-3 and Caf1-Ccr4 deadenylases.

Translation termination. Interacts with eRF1.

127

479

1690

1833

1962

628

908-925

107-123

123-140

1382-1399

1362-1381

1605-1622

47-64

36

77

55

45

75

62

65

15 - 25*

32

PAIP1 (PAIP1_HUMAN, Q9H074)

Repressor in transition initiation.

1313

1095-1112

45

127144;263-278
128-145;
248-264

PAIP2 (PAIP2_HUMAN, Q9BPZ3)

Unknown

1942

81-93

76

344

Ataxin-2 (ATX2_HUMAN. Q99700)

Unknown. Helicase with Zinc finger domain.

798

1202-1219

Anti-proliferative. Recruits Caf1 deadenylase. Inhibits cell cycle
progression.
Anti-proliferative. Recruits Caf1 deadenylase. Inhibits cell cycle
progression.

HELZ (HELZ_HUMAN, P42694)

Deubiquitinating enzyme. Regulator of p53/TP53 stability.

2363

Tob2 (TOB2_HUMAN, Q14106)

USP10 (UBP10_HUMAN, Q14694

Unknown
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TPRD (TPR_HUMAN, P53804)

	
  

	
  
Table 3.1 Survey of 13 human proteins known or predicted to interact with PABPC1
through the PAM2 motif, which is generally embedded within intrinsically disordered
region (IDR). PONDR and/or Globplot predictions identified several segments of IDRs
throughout the proteins analyzed. PAM2 motifs were identified from Pfam searches or
previously published work (36,60). (*: Several predicted IDRs of eRF3b are scattered
within the extensive region of structured domains at C-terminal half; these scattered
IDRs are not taken into account for calculating its % disorder. In addition, eRF3b has
extensive low-complexity regions around PAM2 motif; when these regions are excluded,
its % of disorder drops to 15.) This survey was initiated by Amanda B Chadee and edited
by Chyi-Ying A. Chen and Ann-Bin Shyu.

Four of the PAM2-containing proteins analyzed by PONDR (Tob2, Pan3, eRF3b,
and Tnrc6c, a paralog of Tnrc6 or GW182) are relatively well-characterized, with known
cellular functions. We thus focused on these four proteins to perform additional analysis
using Globplot. The results of this analysis (Figure 3.1 A) corroborated the PONDR
results (Figure 3.1 B) and also highlight regions of low complexity (i.e., sequences with
overrepresentation of a few particular residues), a feature of many proteins containing
IDRs (76). The predicted disordered regions with embedded PAM2 motifs and structured
regions of the four proteins are schematized in (Figure 3.2)
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Figure 3.1 PAM2 motif‐containing proteins contain extensive regions of intrinsic disorder.
Human Tob2, Pan3, Tnrc6c and eRF3b protein sequences were analyzed for
intrinsically disordered or unstructured regions (IDR) by Globplot (A) or PONDER (B)
predictor. The websites are listed in the text. Note that in panel a, blue boxes at the
bottom of each plot depict the predicted IDRs for each protein while structured domains
were shown as green boxes. In panel b, green lines above 0.5 are considered IDRs by
PONDR. Also indicated is the position of PAM2 motif in each protein analyzed (red
box). This analysis was initiated by Amanda B Chadee and edited by Chyi-Ying A. Chen
and Ann-Bin Shyu.

Figure 3.2 Diagram of four representative PAM2-containing PABPC1-interacting proteins
showing PAM2 motifs (red blocks), IDRs (blue wavy lines), clusters of potential
phosphorylation sites (asterisks; each asterisk denotes four Ser/Thr sites within a span
of 10–20 aa), and structured regions (black rectangles and lines). Human Tob2
(Q14106), Pan3 (Q58A45), TNRC6c (Q9HCJ0), and eRF3b (Q8IYD1) amino acid
sequences were analyzed by DISPHOS (DISorder-enhanced PHOSphorylation
predictor; http://www.ist.temple.edu/DISPHOS).
3.2 PAM2 motifs in IDRs are generally located next to a cluster of
phosphorylation sites. We used several web-based protein phosphorylation algorithms
to predict the sites and extent of potential phosphorylation in the IDRs of the PAM2containing proteins listed in Table 3.1. The tools we used included DISPHOS (DISorder-
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enhanced PHOSphorylation predictor, http://www.ist.temple.edu/DISPHOS), Scansite
(locates motifs associated with protein kinase phosphorylation;
http://scansite.mit.edu/motifscan_seq.phtml), PhosphoNET (a repository of known and
predicted information on human phosphorylation sites and their evolutionary
conservation; http://www.phosphonet.ca), and NetPhos 2.0 Server (http://
www.cbs.dtu.dk/services/NetPhos). These algorithms predicted that the IDRs in the
PAM2-containing proteins are also the segments that contain clusters of potential
phosphorylation sites. It is striking that, in all cases except eRF3b, there is at least one
cluster of phosphorylation sites very close to PAM2 motifs (see representative examples
schematically shown in Figure 3.2). These bioinformatics results suggest that PAM2containing proteins have the potential to be hyper-phosphorylated by kinases at clusters
within their IDRs. Based on this, we suspected that the interaction of a PAM2 motif with
the MLLE domain of PABPC1 could be modulated via variable phosphorylation at these
serine/threonine clusters. This regulatory scheme could form the basis by which cells
differentially and selectively control the interaction of PABPC1 with distinct PAM2containing partners during mRNA turnover, translation, and gene silencing.

3.3 Phosphorylation of Tob2 and its ability to interact with PABPC1. To test
whether the interaction of a PAM2 motif with the MLLE domain of PABPC1 is modulated
by the degree of phosphorylation, we first determined whether the extent of Tob2
phosphorylation affects its association with PABPC1. Tob2 is a known phosphoprotein
that can simultaneously interact with Caf1 deadenylase via its structured N-terminal BTG
domain and with PABPC1 via the two PAM2 motifs in the C-terminal IDRs (37,77-79).
Point mutations that change the highly conserved phenylalanines to alanines in each of
the two PAM2 motifs (Tob2-FF mutant) (37) abolish Tob2’s ability to interact with
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PABPC1. Ectopically expressed Tob2, either wild-type (WT) or FF mutant, displays three
distinct bands by Western blot analysis, and in vitro alkaline phosphatase (AP)
pretreatment collapsed the three bands into one major band (Figure 3.3 A, upper left),
indicating that Tob2 proteins can be phosphorylated to different extents. As a control, we
showed that AP pretreatment of TTP, an ARE-binding protein known to be highly
phosphorylated (80,81), effectively removed its phosphates. It is worth noting that the
relative mobilities and intensities of the three bands for Tob2-FF differ from those for WT
Tob2, suggesting a link between its phosphorylation state and its ability to interact with
PABPC1.
Co-immunoprecipitation (co-IP) experiments were then performed to see whether
phosphate removal from Tob2 affects its interaction with PABPC1. To rule out the
possibility that co-precipitation of the proteins is due to their association with RNA, the
co-IP experiments were performed in the presence of RNase A. Ectopically expressed
Tob2-V5 was pulled down and divided into two equal parts, one with AP treatment and
one with mock treatment. Both samples were then incubated with lysate from mycPABPC1- expressing cells. The results showed that phosphatase-treated Tob2 pulled
down more myc-tagged PABPC1 than mock-treated Tob2 that remains phosphorylated
(Figure 3.3 A, upper right).
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Figure 3.3 Effects of alkaline phosphatase treatment on phosphorylation of four PAM2containing proteins and their interactions with PABPC1. (A) Upper left: Alkaline
phosphatase (AP) or control (mock) treatment of immunoprecipitated Tob2-V5, Tob2-FFV5, and TTP-V5 leads to a collapse of multiple higher bands into one band in SDSPAGE. TTP, a highly phosphorylated protein, was used as a positive control for
phosphatase treatment. Upper right: Western blot analysis showing that phosphatasetreated Tob2-V5 pulls down much more myc-PABPC1 than does mock-treated Tob2-V5,
whereas both pull down an equal amount of Caf1. Lower left: Western blot analysis
showing that myc-PABPC1 selectively pulled down the bottom two bands, corresponding
to less-phosphorylated forms of Tob2-V5 and did not pull down Tob2-FF-V5 or GAPDH.
(B) Effects of alkaline phosphatase treatment on phosphorylation of Tnrc6c (left), Pan3
(middle), or eRF3 (right) and their interactions with PABPC1 or other partners. Actin
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served as a negative control. Gray arrowheads denote migration change of HA-Tnrc6c
or Pan3 bands following AP treatment. Cell extracts for IP experiments were prepared
from NIH3T3 cells that were transiently transfected with the plasmids encoding the
proteins indicated.

In contrast, there was no difference in the amount of Caf1 pull-down via the
structured N-terminal domain of Tob2 (Figure 3.3 A, upper right). Together, these
observations suggest that the extent of phosphorylation of Tob2 is inversely proportional
to the strength of its interaction with PABPC1. To corroborate this result, a
complementary co-IP experiment in which cells were co-transfected with myc-PABPC1
and Tob2-V5 was conducted. The result (Figure 3.3 A, lower left) showed that mycPABPC1 selectively pulls down the two less phosphorylated bands of WT Tob2. The
control experiment showed that myc-PABPC1 did not pull down the Tob2-FF mutant,
which lacks the ability to interact with PABPC1 (37). Collectively, we conclude that, while
the two PAM2 motifs of Tob2 are essential for eliciting its interaction with PABPC1, the
extent of Tob2 phosphorylation modulates the strength of this interaction.

3.4 Removal of phosphates from Pan3 and Tnrc6c enhances their
interaction with PABPC1. We next tested whether removal of phosphates from three
other PAM2-containing proteins (Pan3, Tnrc6c, and eRF3b) also enhances their
interaction with PABPC1. Among the three proteins, Tnrc6c is predicted to have the
highest proportion of IDR and potential phosphorylation sites, and eRF3b is predicted to
have the least (Figure 3.2). The results of the co-IP experiments showed that
phosphatase-treated Tnrc6c pulled down appreciably more PABPC1 than the mocktreated one (Figure 3.3 B, left). As expected, phosphatase treatment resulted in a clear
increase of HA-Tnrc6c migration on SDS-PAGE, indicative of removal of an appreciable
amount of phosphates from this protein. In contrast, there was no obvious difference in
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the amount of co-immunoprecipitated Ago2 following phosphatase treatment. Ago2
serves as an internal control giving that Ago2 interacts with N-terminal region of Tnrc6c,
which is away from the PAM2 motif located close to C-terminal region, and Ago2-Tnrc6c
interaction is not affected by the phosphorylation adjacent to the PAM2 motif.
Similarly, phosphatase treatment increased the migration of HA-Pan3 and
increased the amount of co-immunoprecipitated PABPC1 (Figure 3.3 B, middle),
whereas there was only a marginal increase in the amount of Pan2 deadenylase pulldown after phosphatase treatment. Pan2 serves as internal control in the same fashion
as Ago2 in these experiments. In contrast to Tnrc6c and Pan3, HA-eRF3b did not show
any apparent change in its SDS-PAGE migration after phosphatase treatment (Figure
3.3 B, right), consistent with the prediction that this protein has fewer phosphorylation
sites in its IDR compared to other PAM2-containing proteins (Figure 3.2). Moreover,
phosphatase treatment did not change the amount of PABPC1 or eRF1 pulled down by
HA-eRF3b. It is worth noting that eRF3b co-immunoprecipitates much more PABPC1
than Tob2, Pan3, or Tnrc6c does (Figure 3.3), suggesting that eRF3b has stronger
intrinsic PABPC1-binding than the other three proteins. Together, these results support
the notion that the extent of phosphorylation of PAM2-containing proteins modulates the
strength of their interactions with PABPC1.

3.5 Effects of increased phosphorylation of Tob2 and Pan3 on their
interactions with PABPC1. We then used a complementary approach to test whether
increasing phosphorylation of the PAM2-containing proteins affects their interaction with
PABPC1. Cells transfected with Tob2 were first treated with increasing amounts of
Calyculin A, a potent inhibitor of the Ser/Thr phosphatase activities (82) of two major
mammalian phosphatases, PP1 and PP2A (83). The Calyculin A treatment resulted in
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significantly increased phosphorylation of Tob2. This effect appears to be significant for
Tob2 as it was not detected with PABPC1, Caf1, or actin (Figure 3.4 A). The results of
co-IP experiments using these Calyculin A-treated lysates showed that, when the
phosphorylation of Tob2 increased, the amount of PABPC1 (both endogenous and myctagged) pulled down by Tob2 decreased (Figure 3.4 A). In contrast, Calyculin A
treatment had no effect on the ability of Tob2 to pull down Caf1. Together, these results
show that increasing phosphorylation of Tob2 compromised its interaction with PABPC1.
We then tested the effect of Calyculin A treatment on Pan3, Tnrc6, and eRF3b.
The results showed that Calyculin A treatment increased the phosphorylation of Pan3
and also diminished the amount of PABPC1 pulled down by Pan3 (Figure 3.4 B, upper
left). On the other hand, Tnrc6 exhibited only a modest change in SDS-PAGE mobility
after Calyculin A treatment (Figure 3.4 B, upper right), suggesting that little increase in
phosphorylation occurred. As expected, eRF3b showed no migration change (Figure 3.4
B, lower left), indicating that Calyculin A did not elicit an increase in phosphorylation of
eRF3b. The results of co-IP/Western experiments showed that the amounts of PABPC1
pulled down by Tnrc6c and eRF3b were not affected by Calyculin A treatment (Figure
3.4 B, upper right and lower left). Thus, the extent of change in phosphorylation of
PAM2-containing proteins correlated with the degree of change in their interaction with
PABPC1. Calyculin A did not change the electrophoretic migration of PABPC1 (Figure
3.4) or other interacting partners of Pan3, Tnrc6, and eRF3 (Pan2, Ago2, and eRF1,
respectively) (Figure 3.4 B), confirming that phosphorylation of these proteins was minor
if any by Calyculin A. The control experiments showed that Calyculin A treatment did not
change the amount of Pan2, Ago2, or eRF1 pulled down by Pan3, Tnrc6c, or eRF3b,
respectively (Figure 3.4 B). Thus, results from the two complementary approaches of
decreasing and increasing phosphorylation (Figures 3.3, 3.4) support our hypothesis that
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phosphorylation at the Ser/Thr clusters in their IDRs can modulate the interaction of
PAM2-containing proteins with PABPC1.
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Figure 3.4 Effects of Calyculin A treatment on phosphorylation of PAM2-containing
proteins and their interactions with PABPC1. (A) Western blot analysis showing
that Tob2-V5 undergoes dosage-dependent increases in phosphorylation after
Calyculin A (CA) treatment. Myc-PABPC1, endogenous PABP, Caf1, and actin did
not show discernable changes in migration. Immunoprecipitated Tob2-V5 from CAtreated cell lysates pulled down less myc-PABPC1 and endogenous PABP as the
CA concentration increased, whereas no such change was observed for co-IP of
Caf1. (B) Co-IP and Western blotting experiments showing the effects of CA
treatment of Pan3 (upper left), Tnrc6c (upper right), and eRF3 (lower left) on their
interactions with endogenous PABP and other partners. Asterisks denote IP
samples that were further treated with alkaline phosphatase and served as
unphosphorylated controls. Note that eRF3 did not show any discernable change
in its migration. Cell extracts for IP experiments were prepared from NIH3T3 cells
that were transiently transfected with the plasmids encoding the proteins indicated.

3.6 Phosphomimetic mutations in the IDRs of Tob2, Pan3, and Tnrc6c
diminish their interactions with PABPC1. To further test our hypothesis, we created
phosphomimetic mutants of Tob2, Pan3, and Tnrc6c. We targeted the Ser/ Thr residues
within IDRs that are predicted to be phosphorylation sites and are near the PAM2 motif
in each of the three proteins (Figures 3.2 & 3.5). The Ser/Thr residues were changed
either to alanines to create nonphosphorylatable (NP) mutants or to Asp/Glu residues to
create phosphomimetic (PM) mutants. Western blot analysis showed a discernable
difference in the apparent molecular weights between the respective NP and PM
mutants, as expected with different levels of phosphorylation in wild type proteins
(Figure 3.6 A). The results of co-IP experiments (Figure 3.6 A) showed that, in all three
proteins, the PM mutants pulled down much less PABPC1 than did the corresponding
WT proteins, indicating a diminished interaction of PM mutants with PABPC1. On the
other hand, the amounts of PABPC1 pulled down by the NP mutants of Pan3 and
Tnrc6c were similar to those pulled down by the corresponding WT proteins (Figure 3.6
A, left and right). The Tob2 NP mutant pulled down less PABPC1 than did WT Tob2
(Figure 3.6 A, middle). It is unclear whether some of phosphorylation sites might be
important for Tob2-PABP interaction instead of destabilizing the interaction. However, in
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all cases the NP mutant pulled down more PABPC1 than did the corresponding PM
mutant (Figure 3.6 A). Moreover, neither PM nor NP mutations affected the amount of
Caf1 pulled down by Tob2, Pan2 pulled down by Pan3, or Ago2 pulled down by Tnrc6c
(Figure 3.6 A). Collectively, these results further support the notion that phosphorylation
in the IDRs near PAM2 motifs specifically compromises the interaction of PAM2containing proteins with PABPC1.

	
  
	
  
	
  

47	
  

	
  

Figure 3.5 Diagram shows the mutation sites introduced into protein Tob2, Pan3, and
Tnrc6c. Non-phospho mutant is created by changing serine (S) and threonine (T) to
alanine (A). Phospho-mimetic mutant is created by changing serine (S) and threonine
(T) to aspartic acid (D) and glutamic acid (E), respectively. Note that the cluster of
potential phosphorylation sites shown above for Pan3 includes two tyrosine residues that
were also mutated to phenylalanines or glutamates in the respective NP or PM mutant of
Pan3.

3.7 Phosphomimetic mutations alter Tob2, Pan3, and Tnrc6c functions.
Pan3 and Tob2 act as positive regulators of Pan2 and Caf1 deadenylases, respectively,
in a PABPC1-dependent manner. To test the functional significance of the effect of PM
mutations on the interactions of Pan3 and Tob2 with PABPC1 (Figure 3.6 A, left and
middle), cell-based poly (A) size-distribution assay was carried out to determine whether
the PM mutations alter the deadenylation-enhancing function of the proteins (Figure 3.6
B). Total cytoplasmic mRNA was extracted, and the poly(A) tails were labeled at the 3′
end with α-[32P] 3′ - deoxyadenosine (cordycepin) (84), followed by digestion with
RNases T1 and A to remove the mRNA bodies. The resulting poly(A) tail samples were
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then analyzed by denaturing gel electrophoresis. The results showed that WT Pan3 and
Tob2 enhance the Pan2 and Caf1 activities, respectively, resulting in accumulation of
mRNAs with shorter poly (A) tails (Figure 3.6 B). The NP mutants of Pan3 and Tob2
remained capable of enhancing deadenylation mediated by Pan2 and Caf1, respectively,
resulting in poly(A) size-distribution patterns similar to those caused by WT Pan3 or
Tob2 (Figure 3.6 B). In contrast, Pan3 PM and Tob2 PM mutants, which exhibit
diminished interactions with PABPC1, did not enhance Pan2- or Caf1-mediated
deadenylation; the poly(A) tail size distributions were similar to those observed in the
absence of Pan3 or Tob2 (Figure 3.6 B). Together, results from this functional assay
showed that PM mutations near the PAM2 motif in IDRs of Pan3 and Tob2 have a
functional consequence, namely, decreasing the ability of Pan3 and Tob2 to promote
deadenylation mediated by Pan2 and Caf1, respectively.
To test whether PM or NP mutations in the silencing domain of Tnrc6c affect its
function in miRNA-mediated gene silencing, we used an RNA-tethering approach
combined with a dual luciferase assay. λN-peptide (λN), a high-affinity ligand for the
boxB RNA stem–loop, was fused to HA-Tnrc6c and its PM and NP mutants. Each fusion
protein vector was co-transfected with the vector encoding Renilla luciferase (RL) mRNA
that carried four boxB sites in the 3′ UTR (44,85). The results of the dual luciferase
assay showed that WT Tnrc6c effectively repressed RL activity (Figure 3.6 C; compare
to negative control that co-expressed with λN-HA-lacZ). The overall RL activity with
ectopic expression of the Tnrc6c PM mutant was higher than that with the Tnrc6c WT or
the NP mutant (Figure 3.6 C, left), indicating that the PM mutation most impaired the
gene silencing function of Tnrc6c. These results led us to conclude that both NP and PM
mutations in the IDR around the PAM2 motif in Tnrc6c compromise its silencing function,
with the PM mutation having a larger impact than the NP mutation. The observation that
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both PM and NP mutations of Tnrc6c compromise silencing suggests that this silencing
function requires reversible Tnrc6c phosphorylation.

Figure 3.6 Functional impacts of phosphomimetic (PM) and nonphosphorylatable (NP)
mutations on Tob2, Pan3, and Tnrc6. (A) Co-IP and Western blotting experiments
showing effects of nonphosphorylatable (NP) and phosphomimetic (PM) mutations of
Pan3 (left), Tob2 (middle), and Tnrc6c (right) on their interactions with PABPC1 or other
partners. GAPDH served as a control for nonspecific co-IP. (B) Functional effects of NP
and PM mutations of Pan3 (left) and Tob2 (right). Poly(A) size-distribution profile
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analysis for Pan3 and Tob2 was performed as described in Materials and Methods. Cells
were transiently transfected with the plasmids encoding the proteins indicated. Western
blot analysis assesses protein expression levels. (C) Results of dual luciferase assays
showing the gene silencing actions of WT Tnrc6c and its NP and PM mutants.
Histograms (left) show the relative changes of Renilla luciferase (RL) activity detected in
extracts from cells that were transiently co-transfected with a plasmid coding for firefly
luciferase (FL) mRNA and RL mRNA that contain four boxB sites in the 3′ UTR, and a
plasmid coding for λN-HA-Tnrc6c (WT or mutant). The RL/FL activity observed in the
extract expressing λN-HA-lacZ was set at 100%. All data represent the normalized mean
± standard errors (n = 3). Western blot analysis (right) was used to assess the
expression levels of the recombinant proteins. Pan3 panels in figure (A) was performed
by Amanda B Chadee. Figure (C) was performed by Yueqiang Zhang.

Discussion
This study focuses on the PAM2-motif containing partners of PABPC1 in
mammalian cells. Bioinformatics and structural analyses revealed that thirteen human
PAM2-motif containing proteins exhibit similar structural features: (1) They contain IDRs;
(2) PAM2 motifs are embedded within the IDRs; and (3) the PAM2 motifs are near one
or more clusters of potential phosphorylation sites (Figure 3.2; Table 3.1). Based on
these observations, we hypothesized that protein phosphorylation at these Ser/Thr
clusters may modulate the interactions between PABPC1 and the PAM2-containing
proteins. The results of experiments with four of these PAM2- containing proteins (Tob2,
Pan3, Tnrc6c, and eRF3b) support our hypothesis. We thus propose that in the process
of interaction between PABP and PAM2 motif-containing proteins, reversible
phosphorylation at the IDRs near the PAM2 motifs serves to modulate the interaction.
This mechanism may represent a general means to regulate the functions of the various
PAM2-containing proteins in eukaryotes.
The results of the present study support our model. Tob2, Pan3, and Tnrc6c all
can undergo appreciable degrees of reversible phosphorylation. Among the PAM2containing proteins tested here, eRF3b is the least phosphorylated and Tnrc6c is the
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most phosphorylated, while Tob2 and Pan3 appear moderately phosphorylated. Two
complementary approaches showed that the degree of phosphorylation of these PAM2containing proteins correlates inversely with their ability to interact with PABPC1. First,
dephosphorylation by alkaline phosphatase treatment greatly enhances the ability of
Tob2, Pan3, and Tnrc6c proteins to bind to PABPC1 (Figure 3.3). The PABPC1 binding
of eRF3b, whose electrophoretic mobility is not affected by phosphatase treatment, is
not altered by the phosphatase treatment (Figure 3.3 B, right). It is worth noting that
eRF3b is the least phosphorylated of the four proteins and binds more PBAPC1 than the
other three proteins (Figure 3.3). Second, Calyculin A treatment, which greatly increased
phosphorylation of Tob2 and Pan3, decreased their association with PABPC1 (Figure
3.4 A & B, upper left). On the other hand, Calyculin A did not change the apparent
phosphorylation state of eRF3b or alter its interaction with PABPC1 (Figure 3.4 B, lower
left). Calyculin A treatment also did not greatly increase the phosphorylation or decrease
the PABPC1 binding of Tnrc6 (which is predicted to be already highly phosphorylated)
(Figure 3.4 B, upper right).
The amounts of PABPC1 pulled down by Tnrc6 in the co-IP experiments
presented here seem lower than those reported in previous studies (86-88). It is worth
noting that the earlier studies did not use full-length Tnrc6 paralogs for the co-IP
experiments. Instead, the earlier experiments used nonphosphorylated recombinant
Tnrc6, the Tnrc6 silencing domain alone (86,88), or a GFP-Tnrc6 fusion (87) that could
affect phosphorylation and expression of Tnrc6. It is plausible that, in the present study,
Tnrc6 has more phosphorylation and, thus, lower PABPC1 binding. Our finding that
Tnrc6c pulled down more PABPC1 after phosphatase treatment (Figure 3.3 B, left)
supports this notion.
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Functional assays showed that PM mutations of Tob2, Pan3, and Tnrc6c that
diminish their interactions with PABPC1 (Figure 3.6 A) impair their biological functions to
a greater degree than do NP mutants in the same proteins (Figure 3.6 B & C). Pan3 PM
and Tob2 PM mutants were less effective in enhancing the Pan2 and Caf1
deadenylases’ activities in mammalian cells, respectively (Figure 3.6 B). Similarly, the
PM mutant of Tnrc6c exhibited a decreased gene silencing effect (Figure 3.6 C). It
should be noted that the functional impairment seen in PM mutants could have other
explanations, e.g., fortuitous alteration of protein conformation or folding as a result of
introducing a number of Asp/Glu residues. Moreover, as some NP mutants showed
moderately decreased functionality, overly persistent binding of a PAM2 motif-containing
protein to PABPC1 could also hinder the cellular function. Thus, the results here suggest
that the cellular functions of PAM2-containing proteins require their binding to PABPC1
to be both specific and reversible.
Tnrc6c, Pan3, and Tob2 are all positive regulators for mRNA decay, with Tnrc6c
being specific for miRNA targets (37,89-91). Moreover, all three proteins participate in
mRNA decay by promoting deadenylation (13,17). Previously, we showed that mRNA
deadenylation is biphasic, with Pan2-Pan3 and Ccr4-Caf1 involved in the first and
second phases, respectively (16). Through simultaneous interactions with PABPC1 and
Pan2, Pan3 recruits Pan2 deadenylase directly to the 3′ poly(A)-PABPC1 complex to
initiate the first phase of deadenylation (16,89). Tob2 enhances the second phase of
deadenylation by recruiting the Ccr4- Caf1 complex directly to the 3′ poly(A)-PABPC1
complex (37,77,89). Interestingly, Tnrc6c is an integral part of a miRNA-RISC complex
on miRNA-targeted mRNAs, a complex that recruits Pan2-Pan3 and Caf1-Ccr4
deadenylases to the mRNAs without involving PABPC1 (11,92,93). This raises the
question of the functional significance of the interaction between Tnrc6 and PABPC1. A
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recent study (94) shed new light on this issue by showing that PABPC1, through its
interaction with Tnrc6, helps binding of the miRISC complex on the target mRNA during
the early phase of silencing. Subsequently, during the silencing phase, when
deadenylases are recruited, the interaction between PABPC1 and Tnrc6 weakens,
allowing deadenylation to proceed. In light of this observation, we proposed that during
anchoring of miRISC, a less-phosphorylated state of Tnrc6 allows stronger interaction
with PABPC1, whereas during the silencing phase, increasing phosphorylation of Tnrc6
lessens its interaction with PABPC1 and allows deadenylation. One important implication
of the results in the present study is that a global change in miRNA-mediated gene
silencing can be accomplished through signal-dependent, reversible phosphorylation of
Tnrc6 proteins.
In summary, our finding that PAM2-containing proteins generally contain IDRs
and are subject to dynamic phosphorylation provides a framework for understanding
how interactions of various PAM2-containing proteins with PABPC1 are regulated to
coordinate PABPC1’s multiple roles in mRNA turnover and translation. It is worth noting
that the linker between the four RNA-recognition motifs (RRMs) and the MLLE domain in
PABPC1 is also intrinsically disordered according to our analyses using PONDR and
Globplot. Moreover, a recent study (95) reported that PABPC1 is subjected to extensive
post-translational methylation and acetylation, some of which was suggested to impact
the interactions between PABPC1 and PAM2-containing proteins. It will be interesting to
learn if reversible phosphorylation at the IDR in PABPC1 has a role in its interactions
with PAM2-containing proteins. Our findings open up new avenues to decipher the
kinase/phosphatase signaling pathways that modulate the interactions between
PABPC1 and PAM2-containing proteins. Given that most of the RNA- binding proteins in
the mRNA interactome have IDRs (51), the mechanism reported here may represent a
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general new paradigm in which reversible phosphorylation of intrinsically disordered
mRNA-binding proteins helps remodel mRNPs from their biogenesis in the nucleus to
their turnover in the cytoplasm.
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Chapter 4
Phosphorylation regulates Tob2 function on
global mRNA deadenylation
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Introduction
Phosphorylation in eukaryotic cells is well appreciated and involves signal
transduction and every aspect of cellular processes to control from proteins interaction
and activation to metabolism, transcription, translation, and cell proliferation etc. from
prokaryotes to eukaryotes cell (52,96,97). Deadenylation, a process for cells to remove
poly adenosine (A) tail from 3’ end of mature mRNAs and to control mRNA fate, is
demonstrated recently to be regulated by this post translational modification (45). The
majority of eukaryotic mRNAs have a poly(A) tail added at its 3’ end immediately after
being transcribed from DNA (6). The tail length described in yeast and mammals is
around 100 and 250 nucleotides, respectively (17,98). Right after the tail is synthesized,
poly(A) binding proteins (PABPs) instantly harbor on it homogeneously with an average
of 25 adenosines per molecule (24). The poly(A) tail-PABPs complex determines every
aspect of mRNA’s lifespan, starting from maturation, splicing, nuclear exportation,
localization, translation initiation, translation termination, microRNA-mediated gene
silencing, and degradation (2) (Figure 1.1).

PABP is known for its roles in the tail complex as a scaffold protein for various
regulatory proteins to join the tail complex and to control the mRNA functions through
adjusting either the structure of messenger ribonucleoprotein (mRNP) or the length of
poly(A) tail (24). A regulatory protein, eIF4G, creates a closed-loop mRNA structure to
benefit translation efficiency through interaction between the mRNA 5’ cap structure and
PABP (40); two deadenylases Pan2 and Caf1 are recruited to 3’ end of mRNA to
shorten the poly(A) tail by interacting with PABP-binding regulatory proteins Pan3 and
Tob2, respectively (17). The PABP family includes five paralogs in human, four located
in cytoplasm and one in nucleus (24). All PABPs contain RRM motifs in the N-terminal
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region for RNA-binding, but only three cytoplasmic forms have a unique motif, MLLE,
located near the end of C-terminal region for interaction with PABP-interacting motif-2
(PAM2) found in various regulatory proteins (Figure 1.3). Within these three PABPs, one
is testis-specific and another one is inducible form, PABPC1 is the only abundant form of
PABP in cytoplasm to function through interacting with PAM2 motif-containing proteins.
The importance of this interaction can be highlighted by Tnrc6-PABP, which is required
for microRNA-mediated gene silencing(44,61,88).

The current model indicates that only the last PABP at the end of poly (A) tail has
its MLLE domain exposed for interaction with regulatory proteins (34) (Figure 1.5).
Therefore, the mechanism for the MLLE domain to selectively interact with a PAM2
motif-containing protein but not others, and what the impacts these interactions have on
mRNA fate, are still unclear. This chapter describes work using poly (A) tail-PABP-Tob2
interaction as a model to study how the mRNP remodeling is regulated by multi-layer
phosphorylation events leading to adjustment of global deadenylation rate.

Tob2, a protein ubiquitously expressed in all tissues (65,99), belongs to the
BTG/TOB (B-cell translocation gene/transducer of ERBB2) protein family. This family of
proteins is known for its roles in embryonic development, cell cycle progression, antiproliferation, apoptosis, and as a tumor suppressor gene (100-102). All of the six family
members have a highly conserved BTG domain at their N-terminus. In the subfamily of
Tob, the BTG domains of Tob1 and Tob2 share 96% similarity in amino acid sequence
(82% identical in amino acid) and are shown to interact with MAP kinases (Erk2 and
JNK2) in Tob1 (103,104) and with Caf1 deadenylase in both Tob proteins (37,38). Since
the BTG domains from Tob1 and Tob2 are highly conserved, it is plausible that Tob2
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can also interact with Erk2 and JNK2. Distinctively at C-terminal end, Tob proteins have
a long stretch of unstructured region in the C-terminal domain sharing lower (73%)
similarity in amino acid sequence (47% identical in amino acid) (101). Besides, both Tob
proteins have two separated PAM2 motifs embedded inside IDR for PABP interaction, a
unique feature among all PAM2 motif-containing proteins. How these two motifs intramolecularly communicate with each other in terms of PABP interaction is an intriguing
question.

Tob1/2 proteins are discovered to be able to enhance mRNA deadenylation
through direct interaction with Caf1 through BTG domain and interaction with PABP
through its two PAM2 motifs (37). The deadenylation promoting function of Tob2 was
linked to its anti-proliferation function (38,105). Our recent study further demonstrated
that the C-terminal region of Tob2 is highly intrinsically disordered and potentially
multiple-phosphorylated (45). These potential multiple-phosphorylation sites in the
intrinsically disordered regions of PAM2 motif-containing proteins Tob2, Pan3, and Tnrc6
can diminish their interaction with PABP and regulate their functions on mRNA fate upon
phosphorylation (45). In mammals, Tob1 has been shown to be phosphorylated at three
sites by MAP kinases Erk1/2 in intrinsically disordered region (103) to alter their antiproliferation function. However, there are many more sites capable of being
phosphorylated. It is still unclear as to how these multiple phosphorylation sites
cooperate with each other in modulating the Tob2 function of promoting mRNA
deadenylation and anti-proliferation, and what are the signal pathways involved to
control mRNA fate through post-translational modification of Tob2 protein. Furthermore,
the underlying mechanism by which Tob2 regulated the anti-proliferation function is
linked to its ability to promote deadenylation remains elusive.
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This chapter describes results supporting multi-layers of phosphorylationregulated mechanism of Tob2 in mRNP remodeling and mRNA deadenylation, in which
phosphorylation induced by different stimuli can crosstalk at intrinsically disordered
region of Tob2 to control global mRNA stability through synergism of two PAM2 motifs.
Results
4.1 c-Jun N-terminal kinase can trigger Tob2 hyper-phosphorylation and weaken
Tob2-PABP interaction
In our previous study, hyper-phosphorylated Tob2 induced by Calyculin A treatment
was shown to weaken its ability to interact with PABP and reduce its functional impact
on promoting mRNA deadenylation (45). To further dissect the underlying mechanism, it
was imperative to first identify the kinase responsible for Tob2 hyper-phosphorylation.
Taking advantage of the reversible property of inducing hypo-phosphorylation and
hyper-phosphorylation of Tob2, Tob2-expressing cells were pre-treated with several
major kinase inhibitors prior to a phosphatase inhibitor, Calyculin A treatment. An initial
test showed that c-JUN N-terminal kinase inhibitor, SP600125, is a candidate that has
the potential to diminish hyper-phosphorylated Tob2 induced by Calyculin A, suggesting
that Calyculin A-induced hyper-phosphorylated Tob2 may be mainly through JNK
pathway. Hyper-phosphorylation of Tob2 only affects its interaction with PABP, but has
no effect on its interaction with Caf1(45). We then tested the effects of over-expression
with an increasing amount of constitutive-activated JNK1 (CA-JNK1) plasmid on Tob2
phosphorylation. Co-IP western result showed that the hyper-phosphorylated Tob2 band
became stronger when the ectopic expressed CA-JNK1 increased (Figure 4.1). In
addition, it also showed that the more Tob2 is hyper-phosphorylated, the less it can pull
down endogenous PABP (Fig 4.1).
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Figure 4.1 Co-expressing constitutive activated JNK1 and Tob2 in U2OS cells induces
Tob2 hyper-phosphorylation. The more Tob2 is hyper-phosphorylated by increasing
JNK1 expression level, the less PABP is co-immunoprecipitated with it.
Since Tob2 has been shown to be an anti-proliferation factor inhibiting G1
through S phase of cell cycle (65,106), as an effort to find out the physiological
conditions that trigger change of Tob2 phosphorylation pattern, we tested whether
arresting cell cycle in G1/S phase or synchronizing cells in specific phase can induce
Tob2 phosphorylation pattern change. As exposing cells to UV irradiation is known to
induce cell cycle G1 checkpoint arrest, I treated cells with increased dose of UV and
examined whether the treatment can trigger change of Tob2 phosphorylation status and
lead to a change in the PABP affinity (Figure 4.2 A). The results show that the
phosphorylation status of Tob2 is correlated with the dose of UV treatment, and the
more Tob2 is phosphorylated the less it can pull down PABP. When Nocodazole (Noc)
was used to synchronize Tob2-expressing cells in Mitosis phase and subsequently
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removed, reduction of Tob2 phosphorylation was observed and more PABP was pulled
down (Figure 4.2 B).

Figure 4.2 Tob2 hyper-phosphorylation can be triggered by UV or Nocodazole. Tob2
overexpressed cells were (A) exposed to 25 J/m2 and 250 J/m2 of UVC, or (B) treated
with 100ng/ml Nocodazole (NOC) for 18 hours. A Co-IP western was run to check Tob2
phosphorylation pattern and PABP interaction.
These observations are consistent with the notion that activating JNK1 can
induce hyper-phosphorylation of Tob2 and lower binding affinity of Tob2 with PABP.

4.2 Identification of JNK1-induced hyper-phosphorylation sites for Tob2-PABP
interaction
To elucidate the steady-state Tob2 phosphorylation sites and JNK-induced
hyper-phosphorylation sites, we pursued Mass Spectrometry analysis using ectopic
expressed Tob2 protein samples isolated from U2OS cells co-transfected with either
vector alone or CA-JNK1 (Fig 4.3 A). The comparison between these two Tob2 forms
allowed us to identify phosphorylation sites that appeared only when CA-JNK1 was over-
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expressed. Mass Spectrometry analysis results (Fig 4.3 B) not only confirmed that Tob2
has more phosphorylated sites when CA-JNK was co-expressed, but also revealed two
important features of Tob2 phosphorylation pattern: i) The Majority of phosphorylation
sites are located inside the intrinsically disorder region (light blue box), which is in
accordance with the prediction (45) that this region is prone to post-translational
modifications; ii) JNK-induced phosphorylation sites on Tob2 are adjacent to PAM2
motif, which also confirms our previous hypothesis (45) that the interaction between
PAM2 motifs and PABP are controlled by a cluster of phosphorylation sites located near
PAM2 motif.

Figure 4.3 Identify JNK1-induced hyper-phosphorylation sites by Mass Spectrometry. (A)
Western blot result shows steady-state Tob2 phosphorylation pattern and JNK1-induced
hyper-phosphorylation pattern after co-transfection in U2OS cell. (B) Mass Spectrometry
detects common and differential Tob2 phosphorylation sites between non-induced and
induced JNK1. Numbers indicate the confident phosphorylation sites detected. Red
numbers indicate the sites induced by JNK1 over-expression. Gray box indicates nonedetectable sites. Solid red boxes are PAM2 motifs. Light blue box highlights the region of
intrinsically disorder region.
To test the role of these sites in Tob2-PABP interaction, I performed Tob2
mutagenesis assay to create mutants that carry only a single mutation on one of the
common phosphorylation sites or one of the sites that was induced by CA-JNK1 kinase.
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Co-IP western was performed to check whether any of the single site mutation would
change Tob2 phosphorylation pattern and thus alter Tob2-PABP1 interaction. The
results showed that the single JNK-induced phosphorylation site mutation at serine 254,
which is located right inside second PAM2 motif, dramatically affects the Tob2
phosphorylation pattern and Tob2-PABP interaction (Figure 4.4). When Tob2 serine 254
was mutated to alanine to mimic non-phosphorylation form, the middle and top bands
disappeared. This suggests that serine 254 is a phosphorylation site critical for
subsequent phosphorylation elsewhere. Interestingly, opposite from Chapter 3 where
Tob2 with less phosphorylation pulled down more PABP, the phospho-resistant mutant
Tob2 S254A can barely pull down PABP while phospho-mimetic mutant Tob2 S254D
can dramatically enhance Tob2-PABP interaction. Because the serine 254 is in the
second PAM2 motif and is not in the intrinsically disordered region, these results support
a model illustrating two layers of regulation by phosphorylation inside and outside of the
PAM2 motif (see discussion of this chapter).
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Figure 4.4 Mutagenesis study to evaluate the impact of JNK1-induced phosphorylation
sites and common highly confident sites on PABP interaction. U2OS cells were
overexpressed with individual mutant for 24 hours before subjected to co-IP western.
The phospho-mimetic (SàD) and –resistant (SàA) mutations of common
phosphorylation site serine 254 not only have distinct phosphorylation pattern but also
have a dramatically opposite ability to interact with PABP. With S254 changed to A, the
hyper-phosphorylation band was no longer visible, suggesting a priming effect.

Since the Tob2 S254 phosphorylation in the conserved PAM2 motif region plays
a critical role in PABP interaction, it was interesting to learn whether other PAM2 motifcontaining proteins have the same feature in PAM2 motif. Alignment of known human
PAM2 motif-containing proteins revealed that three of them contain a serine at position 4
of the PAM2 motif (Figure 4.5) as in Tob2. Serine 254 of Tob2 is also reported to be
phosphorylated in vivo in previous studies (107-109), and this study demonstrates its
impact on the PAM2 motif interaction with PABP.
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Figure 4.5 Alignment of known PAM2 motifs from Homo sapiens. The canonical motif
sequence is in yellow background with number labeled. Only three proteins carry serine
at position 4 of PAM2 motifs marked in Red. The conserved phenylalanine is marked in
blue in all PAM2 motifs

4.3 S254 phosphorylation of Tob2 enhances mRNA deadenylation in vivo
To study the functional impact of serine 254 of Tob2 in terms of deadenylation, I
performed Northern blotting analysis to measure the deadenylation rates of β-globulin
reporter gene under the influence of vector, Tob2 WT, Tob2 S254A, or Tob2 S254D in
U2OS Tet-off cells (Figure 4.6 A). The overexpressed Tob2 proteins were checked by
western blot to confirm success of transfection (Figure 4.6 B). Profiles of each band
were plotted, and overlapped with the profile of vector alone for better comparison of the
Tob2 effect on deadenylation (Figure 4.6 C). The results show that Tob2 WT alone can
accelerate deadenylation. Phospho-mimetic mutant Tob2 S254D dramatically enhances
the acceleration while phospho-resistant mutant S254A slightly slows down the
acceleration of deadenylation speed. In order to further examine the impact of
phosphorylation at Tob2 S254, I performed poly(A) tail distribution assay to monitor the
global endogenous mRNA deadenylation under the influence of Tob2. Vector or one of
the Tob2 constructs (WT, S254A, & S254D) was transfected into cells, and the length of
total mRNA poly(A) tail was examined to check the effect on deadenylation (Figure 4.7
A). The profiles of each lane were plotted and overlapped with vector alone profile
(Figure 4.7 B). Tob2 S254D mutant makes the pool of mRNA tail shorter than that of
Tob2 WT or S254A.
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Figure 4.6 Tob2 serine 254 phospho-mimetic mutation enhances Tob2 function in
promoting β-globin reporter mRNA deadenylation. B2A2 cells (NIH3T3 Tet-off stable cell
line) were transfected with reporter gene β-globin together with vector or Tob2 plasmids.
Transcriptional pulse-chase experiment was carried out and the cells were harvested in
time course. (A) Northern blot results show that phospho-mimetic S254D mutant
enhances β-globin mRNA reporter deadenylation kinetics comparing to wild type Tob2.
The poly(A)– lane serves as a base line control representing β-globin mRNA without
poly(A) tail. (B) Western blot to check Tob2 wild type and mutants’ protein expression.
(C) The profile of each band was plotted and superimposed to the same time point of
vector expressing cell. The black dot line indicates the position of mRNA without poly(A)
tail.
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Figure 4.7 Tob2 serine 254 phospho-mimetic mutation enhances Tob2 function in
promoting global mRNA deadenylation. U2OS cells were transfected with vector or
Tob2-Wt, -S254A, or –S254D plasmids for 24 hours before total RNA was extracted. (A)
Global poly(A) size distribution assay result shows that Tob2 S254D mutant can further
promote deadenylation as compared to Tob2 wild type. The panel on the bottom is
western blot to check ectopic Tob2 protein expression. (B) Poly(A) size distribution
profile of each lane is plotted and superimposed to the profile of vector alone. V: vector;
Wt: wild type; A: S254A; D: S254D

	
  
Together, the results show that Tob2 phospho-mimetic mutation S254D can
enhance the deadenylation kinetics of reporter mRNA as well as the shortening of global
mRNA poly (A) tail as compared to wild type Tob2. Phospho-resistant mutation may
reduce Tob2 effect on promoting mRNA deadenylation.
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4.4 Multiple phosphorylation outside PAM2 motif of Tob2 reduces PABP
interaction
Since JNK kinase can induce hyper-phosphorylation of Tob2 leading to reduction
of Tob2-PABP interaction, we then tested whether this also occurs in the case of Tob2
with serine 254 phosphorylated. Co-IP western results showed that CA-JNK1 can induce
hyper-phosphorylation and moderate level of phosphorylation on Tob2 S254D and
S254A mutants, respectively. In the meanwhile, the interaction ability of Tob2 WT and
S254 mutants to PABP are all diminished in different extent (Fig 4.8).

Figure 4.8 JNK reduces Tob2-PABP interaction regardless of S254 status. Tob2
WT, S254A, or S254D mutants were co-transfected with either vector alone or CA-JNK1
for 24 hours. Harvested protein lysates were subjected to co-IP western. The results
show that constitutive-activated JNK1 kinase not only targets wild type Tob2 but also
S254 mutants in terms of phosphorylation induction. Hyper-phosphorylated Tob2 S254D
also shows weakened PABP interaction as hyper-phosphorylated wild type Tob2 does.
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This result suggests that when JNK is activated, the ability of Tob2-S254D to
interact with PABP is also reduced.

4.5 PAM2 motifs of Tob2 work synergistically to interact with PABP
To check if there’s functional intra-molecule cross-talk between the two PAM2
motifs, the interactions between PABP and Tob2 carrying different PAM2 mutations,
were tested by Co-IP western (Figure 4.9). The results show that mutation of either
PAM2 motif (F140A, loss of first PAM2 function; F260A, loss of second PAM2 motif
function) causes dramatic reduction of PABP interaction. When both PAM2 motifs are
mutated (Tob2 FF), Tob2 no longer pulls down any PABP. The amount of PABP pulled
down by individual PAM2 motif is much less than that pulled down by two intact PAM2
motifs in WT Tob2, suggesting a synergistic and indispensable role of two PAM2 motifs
for Tob2-PABP interaction. Mutating serine 254 to alanine reduces PABP interaction to a
level similar to that of knocking down individual PAM2 motif. When Tob2 serine 254 is
not phosphorylated, second PAM2 motif alone does not function. Together, these
observations suggest a regulatory role of S254 in controlling the synergism of Tob2
PAM2 motifs in terms of their interactions with PABP (Figure 4.9).
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Figure 4.9 The synergism of Tob2 individual PAM2 motifs with PABP interaction.
Mutagenesis was practiced to create Tob2 mutants carrying either F140A (1F), F260A
(2F), or both (FF) on top of Tob2 WT, S254A, or S254D mutation. U2OS cells were
transfected with these plasmids for 24 hours before co-IP western to detect PABP
interaction ability of each mutant. Co-IP result shows FF mutant with both PAM2 motifs
being knocked out lost PABP interaction, and knocking out first (F140A) or second
(F260A) PAM2 motif in Tob2 wild type or either S254 mutant drastically reduces PABP
interaction.
4.6 Establishment of Tob2 inducible cell line
Tob2 is known for its role as an anti-proliferation protein. Overexpression of
Tob2, results in cell cycle arrest and decrease of cell growth rate (65,106). In order to
study the function of Tob2 on mRNA deadenylation with minimal changes in cell
physiology beforehand, an inducible system is required. Tetracycline-controlled gene
activation was developed to meet timely expression of gene of interest by simply adding
(Tet-on) or removing (Tet-off) the antibiotic tetracycline from the culture medium(110).
This system enables researchers to study the functions of tumor suppressor genes. To
set up this transcriptional pulsing machinery in cells, cells were required to stably
express tetracycline-controlled transcription activator (tTA). In Tet-off system, tTA will
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bind to Tet-responsive element in the absence of tetracycline, and therefore, brings it
transcriptional activation function to the promoter of gene of interest to activate
transcription (Figure 4.10 A). To have a tTA-expressing stable cell line, lentivirus system
is adopted to help insertion of promoter-tTA sequences into the chromosome. Since
binding of tTA to each TRE upstream of a gene contributes to the transcription activation
of the gene, having more tTA would enable the cell to reach higher levels of induction.
To address this notion while establishing cell lines, cells were infected by lentivirus either
once or twice. The expression of tTA is confirmed by western blot (Figure 4.10 B). More
infection times gives higher tTA expression level. HeLa Tet-off cell, which is
commercially available and claimed to have optimal induction, serves as a comparison
base line.

Figure 4.10 Create tTA-expressing U2OS Tet-off stable cell line. To drive transcription of
gene of interest under the control of Tet promoter, cell is required to express
tetracycline-controlled transcription activator (tTA). In the absence of tetracycline, tTA
will bind to Tet promoter and activate transcription (A). Cells, which were infected with
lentivirus carrying tTA gene, were checked for tTA expression level (B). HeLa Tet-off cell
was commercially purchased and served as positive control.
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Since lentivirus introduces tTA gene sequence in a random manner, each cell in
pooled population may behave differently due to this random gene insertion. In order to
have best induction while keeping cells in as normal as possible in terms of morphology
and growth rate comparing to parental cells, a single colony selection was performed.
From one-time infected pool of cells, 30 colonies were picked; from two-times infected
pool of cells, 56 colonies were picked (Figure 4.11). Gene induction (without tetracycline)
and repression (with tetracycline) in each individual colony was tested by delivering
luciferase reporter gene under the control of Tet promoter. Cells, which exhibit either
higher luciferase activity or higher repression rate (luciferase activity with/without
Doxycycline), were first selected. Further narrowing down of candidate cells was
achieved by comparing their morphology and growth rate to that of the parental U2OS
cells. It is interesting to learn that increased frequency of virus infection resulted in
increased morphology and growth changes in cells. Only 2 out of 12 selected cells from
two-times virus infected clones exhibited normal shape and growth rate while 4 out of 8
selected cells from one-time virus infected clones had a better rate of success.
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Figure 4.11 Examination of the capability of each stable cell line to induce and to repress
luciferase gene in the absence and presence of doxycycline, respectively. (A) Thirty
cloned one-time virus infected cells, and (B) fifty-six cloned two-times virus infected cells
were transfected with Tet-promoter-controlled luciferase gene plasmid. The luciferase
activity was measured. Clones that met the induction and repression threshold (red
lines) were picked (red arrow). Cells, which have similar morphology to parental U2OS
cell, were further selected (red rectangle). Four out of eight are normal in (A) while two
out of twelve are normal in (B).
To select the clone for future mRNA deadenylation study, the same test with
different reporter genes was performed on Northern blot system in order to have a more
close-to-real readout to select with (Figure 4.12). Within four clones, all gave good
strong induction of reporter gene shown in shorter exposure film. Considering the extent
of repression shown in longer exposure film, clone 29 gives a superior result having
lowest transcriptional leaky signal smear in the presence of doxycycline. Therefore,
U2OS Tet-off clone 29 was selected for subsequent experiments.
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Figure 4.12 Testing the capability of U2OS Tet-off stable cell lines to induce and to
repress reporter RNA. Four cloned cells were transfected with Tet-controlled β-globin
reporter and internal control GAPDH. Without or with increased amount of doxycycline
was applied to cells for 24hr. Northern blot was performed to check RNA level. Upper
panel, shorter exposure is for better comparison of robust induction; Lower panel, longer
exposure is for better examination of transcriptional leaky from doxycycline repression.
All thin bottom bands of β-globin in lanes with Dox treatment were due to no Dox in the
first 8hr of transfection.
4.7 Optimization of condition for checking Tob2 S254D effect on deadenylation
To study mRNA decay, transcriptional inhibitor actinomycin D has long been
used to shut down RNA polymerase transcription. However, the disadvantages of using
it have been found to alter many mRNA half-life(111-114), nucleus-cytoplasm
shuttling(115,116), and long non-coding RNAs stability(117,118). More recently, an
inhibitor-free method has been developed to metabolically label newly synthesized RNA
with 5’-bromo-uridine and other metabolites. This uridine analog is incorporated into
RNA transcriptionally and has little cytotoxicity (119). Using this compound to measure
mRNA decay, uridine-chasing step is necessary prior to harvesting cell in time course
manner. In these most critical labeling steps, optimization of BrU concentration and
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duration for labeling is essential to achieve highest incorporation. Thus, a transcriptional
pulse-labeling with BrU labeling approach was established in our lab (Figure 4.13).

Figure 4.13 Schematic diagram of pulse-chase bromouridine RNA immunoprecipitation.
(A) 10mM bromouridine (black triangle) is added into cell culture medium to be
incorporated into newly synthesized RNA (red line). (B) After 2 hr labeling, bromouridine
was washed away and replaced with uridine for chasing period. Cells were harvested in
time-course manner. (C) Total RNA was extracted from each time point sample, and
subjected to be immunoprecipitated by anti-BrdU (green symbol) on magnetic beads
(gray ball) followed by elution of bromouridine labeled RNA from beads.
Use of established U2OS Tet-off clone 29 inducible cell line with optimized pulsechase bromouridine RNA Immunoprecipitation, Tob2 effect on promoting deadenylation
of newly synthesized RNA can be measured with the smallest disturbance in cells. Tob2
S254D inducible cell line was then established on top of U2OS Tet-off clone 29, using
the same lentivirus approach. Unlike single colony selection, a pool of Tob2 inducible
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cell was used. To test the effect of Tob2 S254D on endogenous mRNA, Tob2 S254D
was induced to express first, followed by BrU metabolic labeling RNA-IP (Figure 4.14).

Figure 4.14 Schematic diagram shows the usage of metabolic labeling approach to
study the impact of Tob2 on mRNA stability globally. (A) Tob2 (yellow oval) was induced
by removing of doxycycline from cell culture medium. When Tob2’s function, in terms of
promoting deadenylation, reached the highest point, BrU metabolic labeling RNA-IP was
performed (B to D).

To check when Tob2 S254D expression and deadenylation function can be
readily detected, I carried out a time course experiment after induction of Tob2 S254D.
Total RNA extracted from each time point were subjected to poly(A) tail distribution
assay (Figure 4.15 A). Without Tob2 S254D, the normal population of mRNA is
characterized with two typical groups: one with a longer tail with an average size of
around 150 nucleotides and the other one with a shorter tail of around 50 nucleotides.
Because Tob2 S254D enhances shortening of poly(A) tail, the ratio changed between
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these two groups can be calculated. The preliminary results showed that Tob2 S254D
was readily detected in the earliest time point after 6 hours of induction and that the
induction quickly reached to top after the 14-hour removal of doxycycline. By profiling
and counting the two groups of tails distribution percentage (Figure 4.15 B), Tob2 S254D
function reached maximum after 10 hours of induction. Thus, I started the pulse-chase
bromouridine labeling before reaching the 10-hour time point, following removal of
doxycycline. Total RNA from each time point was subjected to poly(A) size distribution
assay to check the effect of Tob2 S254D on deadenylation (Figure 4.16). The reduction
of the top peak from 0 hour of chasing time point (equal to 10 hours after induction of
Tob2 S254D), indicates that Tob2 S254D indeed exerts its function effectively.

Figure 4.15 Estimation of the earliest time point where induced Tob2 S254D exerts
highest function on promoting deadenylation. (A) Doxycycline was removed from U2OS
Tet-off Tob2-S254D-expressing cell. RNA were extracted from cells harvested in time-
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course manner. An equal amount of CPM of each cordycepin-labeled poly(A) tail sample
was subjected to poly(A) tail distribution assay. Two lanes on the right of gel served as
positive control. Lower panels, western blot results showing the Tob2-S254D induction
status of each time point. (B) Profile of each lane resolved on gel was plotted using
Image J software. The two-peak prolife of each image was further divided into two parts
from the center of the groove at molecular weight around 75bp (red dotted line). Ratio of
divided areas of each image was plotted in a bar graph. In each bar, the red colored
portion indicates the longer poly(A) tail ranging from 75 to 250 bp; the blue colored
portion indicates the shorter poly(A) tail ranging from 75 to 25 bp.

Figure 4.16 Poly(A) size distribution assay checking the effect of Tob2 S254D on global
mRNA population. Six time points after removing of bromouridine were selected. Each
time point has two sample comparisons: with or without Tob2-S254D induction. The
bottom panels are western blot showing the expression level of Tob2 S254D in each
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induced time point. The 0 time point on gel is 10 hours after removal of Doxycycline or 2
hours after bromouridine treatment.

4.8 Tob2 anti-proliferation effect is linked to destabilization of cyclin mRNAs
The deadenylation function of Tob2 is required for its anti-proliferation function
(38,53). However, it is still uncertain as to how Tob2 regulates cell growth through
deadenylation. One early study showed that Tob2 prevents cell cycle progression from
G1 to S phase using bromodeoxyuridine-incorporation study to count what percentage of
cells is able to go through G1/S check point under microscope(65). However, the
microscopic study is limited and lacking the scope to cover all phases of cell cycle. With
the successful set up of pulse-chase bromouridine RNA IP deep sequencing system in
our lab, newly synthesized RNAs were metabolically labeled with bromouridine following
Tob2 S254D induction. Cells were collected at different times during the chase period
with uridine. Extracted RNAs were subjected to co-IP with anti-bromouridine antibody
before removal of rRNA and cDNA libraries construction according to Illumina’s protocol.
Preliminary data based on deep sequencing results analyzed with the help from Dr.
Jeffrey Chang suggest that Tob2 S254D preferentially destabilizes major cyclin mRNAs.
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Figure 4.17 Tob2 anti-proliferation effect does not affect cell cycle distribution. (A) The
ratio of cell proliferation rate of each Tet-off stable cell line without over with doxycycline
over a time course was calculated. The number of cells was calculated based on the
amount of DNA. The effect of Tob2-mediated anti-proliferation is further enhanced by
S254D mutation. The western blot panels show the expression of Tob2 protein after 5
days’ induction. (B) Propidium iodide staining with flow cytometry analysis was
performed to check cell cycle distribution after induction of Tob2 genes from 1 to 3 days.
The percentage of each phase of 3 days’ time point of each cell was averaged and
plotted.
The anti-proliferation effect of Tob2 was checked using Tet-off inducible stable
cell lines expressing vector, Tob2 WT, or Tob2 S254D gene after removal of
doxycycline. By calculating the ratio of amount of DNA from cells without (Tob2
expression induced) and with doxycycline (Tob2 expression suppressed), the effect of
vector alone, Tob2 WT, and Tob2 S254D for the period of 5 days’ measurement was
plotted. Meanwhile, the same batches of cells (from 1, 2, and 3 days after induction)
were subjected to cell cycle analysis using flow cytometer. The results confirmed Tob2
WT effect on cell proliferation and also demonstrated that Tob2 S254D mutant can
further enhance Tob2 anti-proliferation function (Figure 4.17 A). While cell proliferation
rate was significantly slowed down by Tob2 without visible cell death (Figure 4.17 A), the
cell cycle phases distribution was not affected by either Tob2 WT or S254D mutant
(Figure 4.17 B). Together, the results suggest that arresting cell growth by Tob2 is, at
least in part, accomplished through reducing major cyclins by destabilizing their mRNAs.
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4.9 CDK1 is likely a major kinase to phosphorylate Tob2 at serine 254
Based on the knowledge of direct interaction of kinase-substrate and the notion
that cells would respond to changes to bring homeostasis back by compensation, we
reasoned that when Tob2 S254A is overexpressed and interferes with the deadenylation
machinery, more kinase(s) specific for this site might dock on this mutant longer.
Therefore, co-immunoprecipitation assay was performed (Figure 4.18 A) for subsequent
Mass spectrometry analysis to identify proteins that interact with Tob2 WT, S254A, and
S254D. The results show that after subtracting nonspecific background binding, 698
proteins were identified to be pulled down by Tob2, 525 by Tob2 S254A, and 550 for
Tob2 S254D (Figure 4.18 B). Among all the kinases identified by Mass spec, CDK1 is
the top hit (16 total peptides detected) and S254A pulled down significantly more
kinases including CDK1 than WT Tob2 or S254D mutant. In addition, several CDK family
members were also identified to interact with Tob2 proteins.
Collectively, the results show that phosphorylation is a critical post-translational
modification controlling Tob2 functions in terms of PABP interaction and global mRNA
deadenylation. These functions can be tuned up or down through phosphorylation of the
serine 254 in the second PAM2 motif.
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Figure 4.18 Mass Spectrometry analysis to identify unique and overlapping interacting
proteins of Tob2 WT and S254 mutants. Tob2-V5 genes were induced for 24 hours
before co-immunoprecipitation of using anti-V5 antibody. Co-immunoprecipitated protein
complexes were subjected to a Mass Spec analysis. (A) Silver staining gel shows the
co-immunoprecipitated proteins complex by vector and Tob2 (WT, S254A, and S254D).
The western blot below shows the induction of each gene. (B) Venn diagram shows the
number of unique and common proteins co-immunoprecipitated by Tob2 proteins.

Discussion
Poly(A)-binding protein (PABP) has been recognized as the key factor involved in
Poly(A) tail mRNP remodeling process to influence mRNA fate. Tob2, among many that
can interact with PABP, is known to promote mRNA deadenylation through recruiting
nuclease Caf1 to the end of poly(A) tail. However, the mechanism of how cell regulates
this function is still unclear. The work described in the previous chapter showed that
phosphorylation at the intrinsically disorder region of PAM2-motif containing proteins
decreases their interaction with PABP and reduces their function. This chapter describes
how we manipulated Tob2 phosphorylation status and identified common and differential
phosphorylation sites between steady-state and JNK1-induced hyper-phosphorylated
condition. A critical phosphorylation site at serine 254 in the second PAM2 motif was
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identified, and it was found that phosphorylation of this site not only enhances PABP
interaction but also accelerates global deadenylation in vivo.
Based on the crystallography X-ray structure of interacting PAM2 motif from
Paip2 and MLLE domain from PABP(39), enhancement of PABP interaction could be
achieved by negatively charged (PO43-) serine 254 in Tob2 (Figure 4.19). According to
the structure, asparagine on 4th position of Paip2 PAM2 motif forms hydrogen bond with
glutamic acid in third α-helix of PABP MLLE domain. If in the case of Tob2 where 4th
position is a phosphorylated serine, it is possible that negative side chains of both amino
acids will repulse each other. Since PAM2 is surrounded by intrinsically disordered
peptides with high flexibility on conformation, the electrical repulsion force would
possibly push phosphorylated serine to the nearest amino acid with positive charged
side chain, which could be histidine 617 or lysine 580. The salt bridge formed then may
be the reason why phosphorylated serine can interact with PABP more strongly.
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Figure 4.19 From co-crystallized structure of PAM2 (from Paip2)-MLLE to hypothesize
Tob2 S254 effect on PABP interaction. (A) MLLE domain of PABP. Positive charged
amino acids (blue) and negative charged amino acids (red) are labeled in α-helix 3 and
α-helix 5. (B) The amino acid asparagine at 4th position (yellow) of PAM2 motif (green
line) forms hydrogen bond with the glutamic acid (red) in α-helix 3 of MLLE domain
(cyan). The distance between the two is 2.6Å. α-helix 3~5 are in bright blue.

On the way of searching for the kinase targeting Tob2 serine S254, the peptide
sequence around the serine is analyzed. The serine is followed by a proline. This SP
motif in the cell is the most popular phosphorylation site for cyclin-dependent kinases
(CDK), mitogen-activated protein kinases (MAPK), c-JUN N-terminal protein kinase
(JNK), etc. This proline-directed serine phosphorylation controls many fundamental
cellular processes including cell proliferation(120). Because of the promiscuous
characteristic of the serine, it is difficult to pinpoint the best kinase at present. In different
cellular conditions and stages, the interacting kinase may vary.

	
  
	
  
	
  

85	
  

	
  
Consistent with the results described in Chapter 3, additional phosphorylation
sites in IDR that are near the two PAM2 motifs can diminish the S254 effects
biochemically and biologically. Noticeably, JNK induced hyper-phosphorylation at
multiple sites were found in the intrinsically disordered region of Tob2. This result
suggests that those sites either play an opposite role in PABP interaction or are involved
in other molecular processes, for example, phosphorylation-directed ubiquitination(121).
Interestingly, the critical region for ubiquitination directed proteasome degradation on
Tob2 was mapped to the end of C-terminal region(122), although the site for
ubiquitination had not been solved. In Tob1 C-terminal, intrinsically disordered region
was shown to interact with Skp2 E3 ligase and subjected to ubiquitin-mediated
proteasome degradation(123). It was observed that Tob2 PM mutant protein expression
level is much stronger than NP mutant when the same amount of plasmid was
transfected into U2OS cell. It is possible that some of phosphorylation sites could control
ubiquitination of Tob2 as a way of controlling the protein stability. Another important
finding is that the two PAM2 motifs of Tob2 worked synergistically in PABP interaction.
When S254 was not phosphorylated, the synergism was lost and the second PAM2
motif alone can no longer pull down PABP.
Lastly, this work suggests that CDK1 is likely a major cyclin-dependent kinase
phosphorylating Tob2 at serine 254. Preliminary data from the transcriptome-based
study supports the role of Tob2 in global mRNA decay and reveals the candidates of
Tob2 targets. The present study also suggests that the anti-proliferation effect of Tob2 is
not through arresting specific stage of cell cycle, but rather is linked to enhancing decay
of cyclin mRNAs, thereby slowing down cell growth. Based on these notions, a Tob2
mRNP remodeling model can be proposed (Figure 4.20). When Tob2 S254 was not
phosphorylated, only the first PAM2 motif interacted with PABP weakly. After
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phosphorylation by CDK1, both PAM2 motifs gained strong ability to interact with PABP,
thereby enhancing Caf1 nuclease processivity at this stage. During the process where
the last PABP was being removed due to digestion of the poly(A) tail, the second PAM2
motif acquired the opportunity to interact with c-terminal MLLE domain of next PABP.
Whenever cells encounter a condition in which JNK signaling pathway is activated, Tob2
will be phosphorylated at multiple sites located in intrinsically disorder region leading to
decrease of deadenylation. This move could be a protective mechanism to give cells
more responding room and time to react with turbulent environmental stresses. In
conclusion, this study indicates that the deadenylation-promoting function of Tob2 is
under the control of an orchestrated multi-layers phosphorylation mechanism.

Figure 4.20 A model showing multi-layer regulations of Tob2 function in deadenylation.
(A) Tob2 interacts with PABP through only first PAM2 motif when S254 is not
phosphorylated. (B) Phosphorylation at S254 by CDK1 enables both PAM2 motifs work
synergistically to enhance deadenylation function by interacting with PABP strongly. (C)
In a circumstance when the JNK pathway is activated, Tob2 will be phosphorylated at
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multiple sites in the intrinsically disordered region. The hyper-phosphorylated Tob2 will
have diminished interaction with PABP. As a result, deadenylation is slowed down.
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Chapter 5
Retrospectives and Perspectives
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It is known that decay of majority mRNAs occurs after deadenylation. Besides,
the poly(A) tail also determines each mRNA's location and translation efficiency. Poly(A)
binding proteins (PABPs) on the tail orchestrate this delicate machinery by interacting
with various proteins, mainly through C-terminal MLLE domain, to determine mRNA fate.
The current model of on-poly(A) tail PABP interaction with PAM2 motif-containing
proteins is that only the last one on tail have available MLLE domain free for interaction
with PAM2 motif. Many different PAM2 motif-containing proteins have their own unique
biological function, but only one PABP on each mRNA tail is available for binding. This
raises the question of how the MLLE domain of PABP is regulated to selectively interact
with various PAM2 motifs containing proteins? Initially, to test if phosphorylation in or
adjacent to the MLLE domain of PABP regulates the selectivity, mutagenesis was
carried out to change predicted phosphorylation sites in PABP C-terminal region, to
either phospho-resistant or phospho-mimetic mutants. Co-immunoprecipitation assay
was used to test whether these mutants have different affinity toward PAM2 motifcontaining proteins, such as Tob2. While preliminary results show that these PABP
mutants pulled down similar amount of Tob2, the Tob2 co-immunoprecipitated by PABP
have a different phosphorylation pattern as compared to steady state pattern, and it
seemed that PABP preferentially interacts with less phosphorylated Tob2. Thus, this
study focused on the role of phosphorylation of PAM2 motif-containing proteins.
Previous prediction by our lab suggested that most of the PAM2 motif-containing
proteins share the same feature with intrinsically disordered region (IDR) in their full
structures. The IDR region is known for its flexible structure and the tendency to be posttranslation modified by phosphorylation. Since PAM2 motifs are embedded in this region
surrounded by many predicted phosphorylation sites, we further hypothesized that
phosphorylation in the IDR region of PAM2 motif-containing proteins regulates its
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interaction with PABP.
The work described in Chapter 3 of this dissertation demonstrated that indeed
multiple phosphorylation in IDR region of well-known PAM2 motif-containing proteins
Tob2, Pan3, and Tnrc6 diminish their interaction with PABP and decrease their
biological functions. The work described in Chapter 4 of this dissertation used Tob2PABP interaction as a model to find the critical phosphorylation site controlling the
interaction of PAM2 motif-containing proteins with PABP because (1) Tob2 has a smaller
IDR region and thus has less predicted phosphorylation sites than Pan3 and TNRC6; (2)
Tob2 has a unique and distinct phosphorylation pattern. It is relatively easy to judge
whether Tob2 is in hyper-phosphorylation status or hypo-phosphorylation status without
using an antibody against the phosphorylation sites. We identified a critical
phosphorylation site (S254) inside the second PAM2 motif of Tob2, which controls the
ability of the second PAM2 motif to interact with PABP and the synergism of the two
PAM2 motifs in terms of PABP interaction. The enhancement of PABP interaction by
phosphorylation at S254 of Tob2 greatly enhances the Tob2 function in promoting
deadenylation. In accordance with the hypothesis in Chapter 3 that multiple
phosphorylations in the IDR region of PAM2 motif-containing proteins dampen their
interaction with PABP, this study also found that hyper-phosphorylated Tob2 induced by
JNK1 reduced its ability to interact with PABP. Mass Spectrometry analysis revealed that
those phosphorylation sites are located in the IDR region adjacent to the PAM2 motif.
Preliminary data from RNA deep sequencing analysis supports the notion that Tob2 antiproliferation is correlated with mRNA destabilization of cyclins, which are known to
control cell cycle progression, hence the rate of cell proliferation. These observations
suggest that Tob2 anti-proliferation function is in part through destabilizing cyclins mRNA
to decrease cyclins level.
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Chapter 4 of this dissertation also described the finding that JNK1 can induce
Tob2 hyper-phosphorylation in vivo. While other PAM2-containing proteins may share
that same pathway for PABP-interaction, each PAM2 motif-containing protein could have
its own unique upstream pathway, receiving different signaling cues and responding to
the PABP-poly(A) tail mRNP. Thus, although multiple phosphorylation events in the IDR
region of PAM2 motif-containing proteins seems to diminish interactions of all PAM2 with
PABP, the phosphorylation events may be induced from different kinases by different
stimuli.

Figure 5.1. Diagram shows the hypothesis
of the feedback loop of deadenylation
regulation and its effect on cell
proliferation. Cyclin-dependent kinase
(CDK) phosphorylates Tob2 at Serine 254,
resulting in enhancement of deadenylation
toward cyclin mRNA. Decrease of cyclins’
stability not only reduces cell proliferations
rate but also disables the CDK kinase
function. In return, Tob2 S254 is less
phosphorylated and cyclins’ transcripts
gain their stability back and restore growth
rate.

	
  

The work described in Chapter 4 also supports that Tob2 S254 can be
phosphorylated by CDK. As our preliminary data support a role of Tob2 S254D phosphomimetic mutant in destabilizing major cyclins, these observations suggest a feedback
loop model between CDK1/cyclins and Tob2 (Figure 5.1). When CDK1/cyclins
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phosphorylate Tob2 at S254, global deadenylation is promoted by Tob2 and cyclins
mRNAs are destabilized; as a result, less proteins are available for CDK activity. Cell
cycle progression is slowed down in all phases, resulting in anti-proliferation effect of
Tob2. On the other hand, dephosphorylation of Tob2 S254 by phosphatase or turnover
of Tob2 protein gives rise to non-phosphorylated S254 of Tob2, which impact the ability
to promote deadenylation. Restoration of cyclins mRNA stability allows CDK protein to
be expressed and thus to phosphorylate Tob2 again.
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